Sagent Pharmaceuticals 10-K 7 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	SGNT
Entity Registrant Name	SAGENT PHARMACEUTICALS, INC.
Entity Central Index Key	1,369,786
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		32,837,857
Entity Public Float			$ 605

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 28,962	$ 55,633
Short-term investments	20,060	18,473
Accounts receivable, net of chargebacks and other deductions	51,425	42,780
Inventories, net	76,453	61,781
Due from related party	2,678	2,156
Prepaid expenses and other current assets	7,388	5,560
Assets held for sale	4,626	0
Total current assets	191,592	186,383
Property, plant, and equipment, net	19,761	71,153
Investment in joint ventures	7,108	4,539
Goodwill	25,184	28,155
Intangible assets, net	53,166	65,575
Non-current deferred tax assets	50,808	23,778
Other assets	2,113	375
Total assets	349,732	379,958
Current liabilities:
Accounts payable	43,703	32,710
Due to related party	13,754	8,079
Accrued profit sharing	7,582	10,684
Accrued liabilities	15,706	19,346
Current portion of deferred purchase consideration		8,725
Current portion of long-term debt	0	508
Notes payable		5,499
Liabilities held for sale	2,910	0
Total current liabilities	83,655	85,551
Long term liabilities:
Long-term debt	1,623	1,945
Deferred income taxes	12,021	15,706
Other long-term liabilities	1,340	2,954
Total liabilities	98,639	106,156
Stockholders' equity:
Common stock - $0.01 par value, 100,000,000 authorized, and 32,801,896 and 31,976,661 outstanding at December 31, 2015 and December 31, 2014, respectively	328	320
Additional paid-in capital	367,235	353,962
Accumulated other comprehensive income (loss)	(17,482)	(3,374)
Accumulated deficit	(98,988)	(77,106)
Total stockholders' equity	251,093	273,802
Total liabilities and stockholders' equity	$ 349,732	$ 379,958

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized shares	100,000,000	100,000,000
Common stock, outstanding shares	32,801,896	31,976,661

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net revenue	$ 318,296	$ 288,983	$ 244,750
Cost of sales	230,557	202,821	167,228
Gross profit	87,739	86,162	77,522
Operating expenses:
Product development	29,145	26,809	20,275
Selling, general and administrative	49,931	43,227	36,198
Acquisition-related costs	2,838	1,069
Management transition	5,310
Equity in net income of joint ventures	(2,569)	(3,987)	(2,395)
Total operating expenses	84,655	67,118	54,078
Impairment of SCP long-lived assets	45,158
Legal Settlement	2,447
Termination fee	0	0	5,000
Gain on previously held equity interest	0	0	2,936
Income (loss) from operations	(44,521)	19,044	31,380
Interest income and other income (expense)	(2,790)	(678)	39
Interest expense	(770)	(2,188)	(930)
Income (loss) before income taxes	(48,081)	16,178	30,489
Provision (benefit) for income taxes	(26,199)	(20,773)	895
Net income (loss)	$ (21,882)	$ 36,951	$ 29,594
Net income (loss) per common share:
Basic	$ (0.67)	$ 1.16	$ 1.01
Diluted	$ (0.67)	$ 1.13	$ 0.99
Weighted-average of shares used to compute net income (loss) per common share:
Basic	32,439	31,882	29,213
Diluted	32,439	32,745	29,937

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Other comprehensive income (loss), net of tax
Foreign currency translation adjustments									(14,080)	(3,830)	790
Reclassification of cumulative currency translation gain											(2,782)
Unrealized gains (losses) gains on available for sale securities									(28)	(31)	(21)
Net current-period other comprehensive loss									(14,108)	(3,861)	(2,013)
Comprehensive income (loss)									$ (35,990)	$ 33,090	$ 27,581

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2012		28,116,489
Beginning Balance at Dec. 31, 2012	$ 131,855	$ 281	$ 272,725	$ 2,500	$ (143,651)
Issuance of common stock (in shares)		3,542,470
Issuance of common stock	70,580	$ 36	70,544
Exercise of stock options (in shares)		130,389
Exercise of stock options	717	$ 1	716
Stock compensation expense	5,293		5,293
Comprehensive income (loss)	27,581			(2,013)	29,594
Ending Balance (in shares) at Dec. 31, 2013		31,789,348
Ending Balance at Dec. 31, 2013	236,026	$ 318	349,278	487	(114,057)
Exercise of stock options (in shares)		178,313
Exercise of stock options	1,023	$ 2	1,021
Stock compensation expense	2,683		2,683
Tax benefit from stock exercises	980		980
Comprehensive income (loss)	33,090			(3,861)	36,951
Ending Balance (in shares) at Dec. 31, 2014		31,976,661
Ending Balance at Dec. 31, 2014	$ 273,802	$ 320	353,962	(3,374)	(77,106)
Exercise of stock options (in shares)	794,528	825,235
Exercise of stock options	$ 9,353	$ 8	9,345
Stock compensation expense	3,836		3,836
Tax benefit from stock exercises	92		92
Comprehensive income (loss)	(35,990)			(14,108)	(21,882)
Ending Balance (in shares) at Dec. 31, 2015		32,801,896
Ending Balance at Dec. 31, 2015	$ 251,093	$ 328	$ 367,235	$ (17,482)	$ (98,988)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net income (loss)	$ (21,882)	$ 36,951	$ 29,594
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	13,681	9,524	7,074
Stock-based compensation	3,836	2,683	5,293
Equity in net income of joint ventures	(2,569)	(3,987)	(2,395)
Dividends from unconsolidated joint ventures		1,511	4,318
Gain on previously held equity interest	0	0	(2,936)
Deferred income taxes, net	(28,025)	(23,732)
Impairment charge	45,158
Other	1,117	(1,180)	(115)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	(9,250)	(16,442)	8,578
Inventories, net	(20,564)	(1,713)	3,053
Prepaid expenses and other current assets	(2,571)	2,171	(3,466)
Due from related party	(522)	(1,208)	(6,924)
Accounts payable and other accrued liabilities	14,068	17,621	7,477
Net cash provided by (used in) operating activities	(7,523)	22,199	49,551
Cash flows from investing activities
Capital expenditures	(6,711)	(4,242)	(1,103)
Acquisition of business, net of cash acquired	(11,785)	(86,467)	(12,996)
Purchases of investments	(13,212)	(87,171)	(275,198)
Sale of investments	11,420	181,352	196,728
Purchase of product rights	(1,707)	(4,404)	(5,174)
Other		0	586
Net cash (used in) provided by investing activities	(21,995)	(932)	(97,157)
Cash flows from financing activities
Increase (reduction) in short-term borrowings	(5,189)	1,152
Repayment of long-term debt	(471)	(10,420)	(8,961)
Proceeds from issuance of common stock, net of issuance costs	9,345	1,023	71,247
Payment of deferred financing costs	(274)	(285)	(28)
Excess tax benefits on stock option exercises	92	980
Net cash (used in) provided by financing activities	3,503	(7,550)	62,258
Effect of exchange rate movements in cash	(656)	(416)	(7)
Net increase (decrease) in cash and cash equivalents	(26,671)	13,301	14,645
Cash and cash equivalents, at beginning of period	55,633	42,332	27,687
Cash and cash equivalents, at end of period	28,962	55,633	42,332
Supplemental disclosure of cash flow information
Acquisition of property, plant and equipment in accounts payable	(856)	934
Cash paid for interest	414	1,361	$ 652
Cash paid for taxes	$ 4,340	$ 2,555

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1. Summary of Significant Accounting Policies: Nature of Operations Sagent Pharmaceuticals, Inc. (“Sagent”, “we”, “us” or “our”) is a leading provider of affordable pharmaceuticals to the hospital market, which we sell primarily throughout North America. We completed our initial public offering (“IPO”) on April 26, 2011. In connection with our IPO, we incorporated (the “Reincorporation”) in Delaware as Sagent Pharmaceuticals, Inc. Prior to the Reincorporation, we were a Cayman Islands company, and our corporate name was Sagent Holding Co. (“Sagent Holding”). Our products are typically sold to pharmaceutical wholesale companies which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The injectable pharmaceutical marketplace is comprised of end users who have relationships with group purchasing organizations (GPOs) or specialty distributors that focus on a particular therapeutic class. GPOs enter into product purchasing agreements with Sagent and other pharmaceutical suppliers for products in an effort to secure favorable drug pricing on behalf of their end-user members. Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The consolidated financial statements include the assets, liabilities, and results of operations of Sagent Pharmaceuticals, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Sagent Agila LLC (“Sagent Agila”) is a joint venture incorporated in Wyoming with Strides Inc., a wholly-owned subsidiary of Strides Arcolab International Limited (“Strides”), established in January 2007 with the principal business of development, manufacturing, marketing, distribution and sale of generic pharmaceutical products to the U.S. market. In December 2013, Mylan Inc. (“Mylan”) acquired Strides’ Agila Specialities Pvt. Ltd., subsidiary (“Agila”), including Strides’ ownership share of the Sagent Agila joint venture. We account for our 50% interest in Sagent Agila under the equity method of accounting as our interest in the entity provides for joint financial and operational control. Sagent’s equity in the net income (loss) of Sagent Agila is included in the accompanying consolidated statements of operations as equity in net income (loss) of joint ventures. On June 4, 2013, we acquired the remaining 50% equity interest in Kanghong Sagent (Chengdu) Pharmaceutical Co. Ltd. (“KSCP”) from our former joint venture partner (the “SCP Acquisition”), and accordingly, the consolidated financial statements since that date include KSCP as a wholly-owned subsidiary. Prior to the SCP Acquisition, we accounted for our investment in KSCP using the equity method of accounting, as our interest in the entity provided for joint financial and operational control, and the operating results of KSCP were reported on a one-month lag. In August 2013, we formally changed the name of this entity to Sagent (China) Pharmaceuticals Co., Ltd. (“SCP”). On October 1, 2014, we, through our wholly-owned subsidiary, Sagent Acquisition Corp., a Canadian company, acquired all of the issued and outstanding shares of the capital stock of 7685947 Canada Inc., and its subsidiary, Omega Laboratories Limited (collectively, “Omega”), a privately held Canadian pharmaceutical and specialty healthcare products company for C$92.8 million ($82.7 million). As a result of the completion of the transaction, Omega became a wholly-owned subsidiary of the Company effective October 1, 2014. As a result of the Omega acquisition on October 1, 2014, we began operating in two reportable segments comprised of operations in the United States, including our Chinese manufacturing site, (Sagent US segment) and Canada (Omega segment), each of which develop, source, manufacture and market generic injectable products for sale within the their respective countries, each segment deriving a significant portion of its revenues from a single class of pharmaceutical wholesale customers within that country. On December 29, 2015, our Board of Directors authorized us to proceed with a sale of all of the Company’s ownership interests in SCP. Following this decision, we have classified SCP as held for sale in our Consolidated Balance Sheet as of December 31, 2015. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Foreign Currencies We translate the results of operations of our foreign subsidiaries using average exchange rates during each period, whereas balance sheet accounts are translated using exchange rates at the end of each period. We record currency translation adjustments as a component of equity. Transaction gains and losses are recorded in interest income and other in the statements of operations, and were $2,838 and $1,075 of transaction losses in the year ended December 31, 2015 and 2014, respectively. Transaction gains and losses were not significant for the year ended December 31, 2013. Fair Value of Financial Instruments The carrying amounts reported in the balance sheets for cash and cash equivalents and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments. Cash and Cash Equivalents These amounts are stated at cost, which approximates fair value. At December 31, 2015, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances. The majority of our funds at December 31, 2015 were maintained at stable financial institutions, in amounts in excess of federally insured limits. This represents a concentration of credit risk. We have not experienced any losses on our deposits of cash and cash equivalents to date. Cash collateral pledged under various lease agreements and cash restricted by financing agreements is classified as restricted cash within the other assets caption in the accompanying consolidated balance sheets as our ability to withdraw the funds is contractually limited. Financial Instruments We consider all highly liquid money market investments with a maturity of three months or less at the date of purchase to be cash equivalents. The carrying values of these investments approximate their fair values. Investments with original maturities of greater than three months and remaining maturities of less than one year are classified as short-term investments. Investments with maturities beyond one year are classified as short-term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. All cash equivalents and short-term investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income (“OCI”). Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. We employ a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, we evaluate, among other factors, general market conditions, credit quality of debt instrument issuers, the duration and extent to which the fair value is less than cost, and for equity securities, our intent and ability to hold, or plans to sell, the investment. For fixed income securities, we also evaluate whether we have plans to sell the security or it is more likely than not that we will be required to sell the security before recovery. We also consider specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to other expense and a new cost basis in the investment is established. Inventories Inventories are stated at the lower of cost (first in, first out) or market value. Inventories consist of products currently approved for marketing and may include certain products pending regulatory approval. From time to time, we capitalize inventory costs associated with products prior to receiving regulatory approval based on our judgment of probable future commercial success and realizable value. Such judgment incorporates management’s knowledge and best judgment of where the product is in the regulatory review process, market conditions, competing products and economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. If final regulatory approval for such products is denied or delayed, we may need to reserve for and expense such inventory. We record inventory provisions for products which have not received regulatory approval within product development expense. We establish reserves for inventory to reflect situations in which the cost of the inventory is not expected to be recovered. In evaluating whether inventory is stated at the lower of cost or market, management considers such factors as the amount of inventory on hand, estimated time required to sell such inventory, remaining shelf life and current expected market conditions, including level of competition. We record provisions for inventory to cost of goods sold. Property, Plant, and Equipment Property, plant, and equipment is stated at cost, less accumulated depreciation. The cost of repairs and maintenance is expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Provisions for depreciation are computed for financial reporting purposes using the straight-line method over the estimated useful life of the related asset and for leasehold improvements over the lesser of the estimated useful life of the related asset or the term of the related lease as follows: Land and land improvements Indefinite, except with respect to the Chinese land use right (through remaining term, June 2057) Building and improvements 5 to 40 years or remaining term of lease Machinery, equipment, furniture, and fixtures 3 to 10 years Software 3 to 5 years Property, plant and equipment that is purchased or constructed which requires a period of time before the assets are ready for their intended use are accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including installation costs and associated interest costs. Construction-in-progress is transferred to specific property, plant and equipment accounts and commences depreciation when these assets are ready for their intended use. The capitalization of interest costs commences when expenditures for the asset have been made, activities that are necessary to prepare the asset for its intended use are in progress and interest cost is being incurred. The capitalization period ends when the asset is substantially complete and ready for its intended use. Deferred Financing Costs Deferred financing costs related to the issuance of debt are amortized using the straight-line method over the term of the related debt instrument, which approximates the effective interest method. We capitalized deferred financing costs of $274 in 2015 in connection with our amended and restated senior secured credit facility with Chase (the “Amended Chase Agreement”) and $285 in 2014 in connection with our new revolving loan credit facility with Chase (the “Chase Agreement”). Deferred financing costs are recorded within Other Assets on our consolidated balance sheets, as there are no outstanding balances related to these loans, and totaled $468 and $275 at December 31, 2015 and 2014, respectively. Impairment of Long-Lived Assets We evaluate long-lived assets, including intangible assets with definite lives, for impairment whenever events or other changes in circumstances indicate that the carrying value of an asset may no longer be recoverable. An evaluation of recoverability is performed by comparing the carrying values of the assets to projected future undiscounted cash flows, in addition to other quantitative and qualitative analyses. Judgments made by management related to the expected useful lives of long-lived assets and the ability to realize undiscounted cash flows in excess of the carrying amounts of such assets are affected by factors such as changes in economic conditions and changes in operating performance. Upon indication that the carrying values of such assets may not be recoverable, we recognize an impairment loss as a charge against current operations. We recorded an impairment charge within cost of sales of $200 related to one product license right in the year ended December 31, 2014. In December 2015, we recorded an impairment charge within operating expense of $45,158 related to classifying SCP as held for sale. Product Development Agreements Product development costs are expensed as incurred. These expenses include the costs of our internal product development efforts and acquired in-process research and development, as well as product development costs incurred in connection with our third-party contract research and development efforts. Non-refundable contractual payments made under contract research and development arrangements for future research and development activities prior to regulatory approval, including payments made upon execution of a definitive contract research and development agreement, are deferred and are expensed as the related services are performed. If we determine that it is no longer probable that the product will be pursued, any related capitalized amount is expensed in the current period. Contractual payments due to a counterparty for development efforts that are contingent upon the successful completion of certain activities are expensed when the successful completion is considered probable. Once a product receives regulatory approval, we record any contractual payments for the license to sell the developed product as an intangible asset to be amortized on a straight-line basis as a component of cost of sales over the shorter of the related license period or the estimated life of the acquired product. At December 31, 2015, the amortization period for intangible assets arising from approved products ranges from four to six years with a weighted-average period prior to the next renewal or extension of 4.3 years. We make the determination whether to capitalize or expense amounts related to the development of new products and technologies through agreements with third parties based on our ability to recover our cost in a reasonable period of time, generally the initial license term, from the estimated future cash flows anticipated to be generated pursuant to each agreement. Market, regulatory and legal factors, among other things, may affect the realizability of the projected cash flows that an agreement was initially expected to generate. We regularly monitor these factors and subject capitalized costs to periodic impairment testing. Goodwill and Intangible Assets Goodwill is recognized as the excess of fair value of consideration transferred to acquire an entity over the fair values assigned to assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for impairment on an annual basis and more often if circumstances require. We assess goodwill impairment risk by first performing a qualitative review of entity-specific, industry, market and general economic factors for each of our reporting units. If significant potential goodwill impairment risk exists, we apply a two-step quantitative test. Impairment losses are recognized whenever the implied fair value of goodwill is less than its carrying value. We test goodwill for impairment at least annually on October 1. Certain amounts paid to third parties related to the development of new products and technologies are capitalized and included within intangible assets. We determine the estimated fair values of certain intangible assets with definitive lives utilizing valuations performed by management at the time of their acquisition, based on anticipated future cash flow activity. We test indefinite-lived intangible assets for impairment by first performing a qualitative review by assessing events and circumstances that could affect the fair value or carrying value of the indefinite-lived intangible asset. If significant potential impairment risk exists for a specific indefinite-lived intangible asset, we quantitatively test for impairment by comparing the fair value of each intangible asset with its carrying value. Fair value of non-amortizable intangible assets is determined using planned growth rates, market-based discount rates and estimates of royalty rates. If the carrying value of the asset exceeds its fair value, the intangible asset is considered impaired and is reduced to its estimated fair value. Definite-lived intangible assets are amortized over their estimated useful lives and evaluated for impairment on a quarterly basis as long-lived assets. Acquired In-Process Research and Development The fair value of in-process research and development (“IPR&D”) projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off to product development expense. Development costs incurred after the acquisition are expensed as incurred. Advertising and Promotion Expense All advertising and promotion costs are expensed as selling, general, and administrative expenses when incurred. Total direct advertising and promotion expense incurred was $1,173, $1,112, and $766 for the years ended December 31, 2015, 2014 and 2013, respectively. Income Taxes Provisions for federal, state and foreign taxes are calculated based on pre-tax earnings at currently enacted tax rates. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss and capital loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the financial statements in the period that includes the legislative enactment date. We recognize the financial statement effects of a tax position only when it is more likely than not that the position will be sustained upon examination and recognize any interest and penalties accrued in relation to unrecognized tax benefits in income tax expense. We establish valuation allowances against deferred tax assets when it is more likely than not that the realization of those deferred tax assets will not occur. In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We also consider the scheduled reversal of deferred tax liabilities, projected future taxable income or losses, and tax planning strategies in making this assessment. Revenue Recognition – General We recognize revenue when our obligations to a customer are fulfilled relative to a specific product and all of the following conditions are satisfied: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) delivery has occurred. Delivery is deemed to have occurred upon customer receipt of product, upon fulfillment of acceptance terms, if any, and when no significant contractual obligations remain. Net sales reflect reductions of gross sales for estimated wholesaler chargebacks, estimated contractual allowances, estimated product returns and estimated early payment discounts. We provide for estimated product returns at the time of sale based on historic product return experience. In the case of new products for which the product introduction is not an extension of an existing line of product, where we determine that there are not products in a similar therapeutic category, or where we determine the new product has dissimilar characteristics with existing products, such that we cannot reliably estimate expected returns of the new product, we defer recognition of revenue until the right of return no longer exists or until we have developed sufficient historical experience to estimate sales returns. Shipping and handling fees billed to customers are recognized in net revenue. Other shipping and handling costs are included in cost of goods sold. Revenue Recognition – Chargebacks The majority of our products are distributed through independent pharmaceutical wholesalers. In accordance with industry practice, sales to wholesalers are initially transacted at wholesale list price. The wholesalers then generally sell to an end user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously contractually established between the end user and Sagent. When we initially record a sale to a wholesaler, the sale and resulting receivable are recorded at our list price. However, experience indicates that most of these selling prices will eventually be reduced to a lower, end-user contract price. Therefore, at the time of the sale, a contra asset is recorded for, and revenue is reduced by, the difference between the list price and the estimated average end-user contract price. This contra asset is calculated by product code, taking the expected number of outstanding wholesale units sold that will ultimately be sold under end-user contracts multiplied by the anticipated, weighted-average contract price. When the wholesaler ultimately sells the product, the wholesaler charges us, or issues a chargeback, for the difference between the list price and the end-user contract price and such chargeback is offset against the initial estimated contra asset. Periodically, we review the wholesale list prices for our products, and from time to time may reduce list prices based on market conditions or competitive pricing pressures. Reductions in the wholesale list price of our products reduce both our gross sales and the revenue reduction recorded upon initial product sale, but do not change the end-user contract selling price. The significant estimates inherent in the initial chargeback provision relate to wholesale units pending chargeback and to the ultimate end-user contract-selling price. We base the estimate for these factors on product-specific sales and internal chargeback processing experience, estimated wholesaler inventory stocking levels, current contract pricing and our expectation for future contract pricing changes. Our chargeback provision is potentially impacted by a number of market conditions, including: competitive pricing, competitive products, and other changes impacting demand in both the distribution channel and end users. We rely on internal data, external data from our wholesaler customers, and management estimates to estimate the amount of inventory in the channel subject to future chargeback. The amount of product in the channel is comprised of both product at the wholesaler and product that the wholesaler has sold, but not yet reported as end-user sales. Physical inventory in the channel is estimated by the evaluation of our monthly sales to the wholesalers and our knowledge of inventory levels and estimated inventory turnover at these wholesalers. Our total chargeback accrual was $48,588 and $63,088 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable. Our total chargeback expense was $318,605, $403,493, and $300,835 for the years ended December 31, 2015, 2014 and 2013, respectively. Revenue Recognition – Cash Discounts We offer cash discounts, approximating 2% of the gross sales price, as an incentive for prompt payment and occasionally offer greater discounts and extended payment terms in support of product launches or other promotional programs. Our wholesale customers typically pay within terms, and we account for cash discounts by reducing net sales and accounts receivable by the full amount of the discount offered at the time of sale. We consider payment performance and adjust the accrual to reflect actual experience. Our total accrual for cash discounts was $3,917 and $2,440 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable. Revenue Recognition – Sales Returns Consistent with industry practice, our return policy permits customers to return products within a window of time before and after the expiration of product dating. We provide for product returns and other customer credits at the time of sale by applying historical experience factors. We provide specifically for known outstanding returns and credits. The effect of any changes in estimated returns is taken in the current period’s income. We determine our estimate of the sales return accrual primarily based on historical experience, but also consider other factors that could impact sales returns. These factors include levels of inventory in the distribution channel, estimated shelf life, product recalls, timing of product returns relative to expiry, product discontinuances, price changes of competitive products, and introductions of competitive new products. Our total accrual for returns and credits was $7,042 and $15,860 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable. Revenue Recognition – Contractual Allowances Contractual allowances, generally rebates or administrative fees, are offered to certain wholesale customers, GPOs, and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to five months from date of sale. We provide a provision for contractual allowances at the time of sale based on the historical relationship between sales and such allowances. Contractual allowances are reflected in the consolidated financial statements as a reduction of revenues and as a current accrued liability. Stock Based Compensation We recognize compensation cost for all share-based payments (including employee stock options) at fair value. We use the straight-line attribution method to recognize stock based compensation expense over the vesting period of the award. Options currently granted generally expire ten years from the grant date and vest ratably over a four-year period. Stock based compensation expense for performance based options is measured and recognized if the performance measures are considered probable of being achieved. We evaluate the probability of the achievement of the performance measures at each balance sheet date. If it is not probable that the performance measures will be achieved, any previously recognized compensation cost would be reversed. We use the Black-Scholes option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under the stock participation plan. Stock-based compensation expense was $3,836, $2,683 and $5,293 for the years ended December 31, 2015, 2014 and 2013, respectively. Recently Adopted and Pending Accounting Standards In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB approved a one year deferral to the new revenue guidance, and we are therefore required to adopt the new guidance on January 1, 2018 using one of the two prescribed retroactive methods. We are evaluating the impact of the amended revenue recognition guidance on our consolidated financial statements. In February 2015, the FASB issued amended guidance on the model used to evaluate whether certain legal entities should be consolidated. This guidance is effective for the Company in the first quarter of 2017. Early adoption is permitted. Adoption of this guidance is not expected to have a material impact on our financial statements. In April 2015, the FASB issued amended guidance, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim periods beginning after December 15, 2015. Adoption of this guidance in the first quarter 2016, is not expected to have a material impact on our financial statements. In September 2015, the FASB issued guidance that eliminates the requirement to restate prior period financial statements for measurement period adjustments related to business combinations. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. In addition, separate presentation on the face of the income statement or disclosure in the notes to the financial statements is required regarding the portion of the adjustment recorded in current period earnings. We are required to adopt this guidance prospectively for measurement period adjustments that occur after the effective date. This guidance is effective for the Company in the first quarter of 2016. Early adoption is permitted. We have adopted this guidance in the current period. There was no material impact of adoption. In November 2015, the FASB issued guidance that requires all deferred tax assets and liabilities to be presented as non-current in a classified statement of financial position. We are required to adopt this guidance by the first quarter of 2017, with early adoption permitted. We have adopted this guidance in our Consolidated Balance Sheet as of December 31, 2015 and retrospectively for December 31, 2014. Adoption of this standard resulted in the reclassification of $12,135 of current deferred tax assets to long term deferred tax assets at December 31, 2014. In February 2016, the FASB issued lease guidance, which is intended to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. In order to meet that objective, the new standard requires recognition of the assets and liabilities that arise from leases. A lessee will be required to recognize on the balance sheet the assets and liabilities for leases with lease terms of more than 12 months. Accounting by lessors will remain largely unchanged from current U.S. generally accepted accounting principles. The

Restatement

Restatement	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Restatement	Note 2. Restatement: We have restated our financial statements for the year ended December 31, 2014 for the correction of errors primarily related to our previous tax filing position relating to SCP during the time SCP was 50% owned and prior to our acquisition of 100% ownership of SCP in June 2013. The error resulted in our incorrectly claiming net operating loss carryforward benefits in the U.S. related to SCP, resulting in an overstatement of deferred tax asset, for which there was a full valuation allowance reserve. In December 2014, we concluded that the valuation allowance against our net U.S. deferred tax assets was no longer required, based on our then recent income and projections of sustained profitability. As a result, we released the allowance in full, including $2,538 related to net operating loss carryforward benefits recognized as a result of the incorrect SCP tax filing position, which resulted in the improper recognition of net income in the year ended December 31, 2014. We also corrected individually immaterial adjustments as part of this restatement related to the overstatement of federal and state net operating losses. The correction of errors resulted in a reduction of $2,930 to net income, or $0.09 per diluted share, for the year ended December 31, 2014. The account balances labeled “As Reported” in the following tables for the year ended December 31, 2014 represent the previously reported financial statements as presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The effects of these prior period errors on the consolidated financial statements after the retrospective adoption of deferred tax asset and liability presentation guidance as described in Note 1, are as follows: Consolidated Statements of Operations (in thousands, except per share amounts) Year ended December 31, 2014 As reported Adjustments As restated Net revenue $ 288,983 $ — $ 288,983 Cost of sales 202,821 — 202,821 Gross profit 86,162 — 86,162 Operating expenses: Product development 26,809 — 26,809 Selling, general and administrative 43,227 — 43,227 Acquisition-related costs 1,069 — 1,069 Equity in net income of joint ventures (3,987 ) — (3,987 ) Total operating expenses 67,118 — 67,118 Income (loss) from operations 19,044 — 19,044 Interest income and other income (expense) (678 ) — (678 ) Interest expense (2,188 ) — (2,188 ) Income (loss) before income taxes 16,178 — 16,178 Provision (benefit) for income taxes (23,703 ) 2,930 (20,773 ) Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Net income (loss) per common share: Basic $ 1.25 $ (0.09 ) $ 1.16 Diluted $ 1.22 $ (0.09 ) $ 1.13 Weighted-average of shares used to compute net income (loss) per common share: Basic 31,882 — 31,882 Diluted 32,745 — 32,745 Consolidated Statements of Comprehensive Income (Loss) (in thousands) Year ended December 31, 2014 As reported Adjustments As restated Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Other comprehensive income (loss), net of tax Foreign currency translation adjustments (3,830 ) — (3,830 ) Unrealized gains (losses) gains on available for sale securities (31 ) — (31 ) Total other comprehensive income (loss), net of tax (3,861 ) — (3,861 ) Comprehensive income (loss) $ 36,020 $ (2,930 ) $ 33,090 Consolidated Balance Sheet (in thousands, except per share amounts) As of December 31, 2014 As reported Adjustments As restated Assets Current assets: Cash and cash equivalents $ 55,633 $ — $ 55,633 Short-term investments 18,473 — 18,473 Accounts receivable, net of chargebacks and other deductions 42,780 — 42,780 Inventories, net 61,781 — 61,781 Due from related party 2,156 — 2,156 Prepaid expenses and other current assets 5,560 — 5,560 186,383 — 186,383 Property, plant, and equipment, net 71,153 — 71,153 Investment in joint ventures 4,539 — 4,539 Goodwill 28,155 — 28,155 Intangible assets, net 65,575 — 65,575 Non-current deferred tax assets 25,308 (1,530 ) 23,778 Other assets 375 — 375 Total assets $ 381,488 $ (1,530 ) $ 379,958 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 32,710 $ — $ 32,710 Due to related party 8,079 — 8,079 Accrued profit sharing 10,684 — 10,684 Accrued liabilities 19,346 — 19,346 Current portion of deferred purchase consideration 8,725 — 8,725 Current portion of long-term debt 508 — 508 Notes payable 5,499 — 5,499 Total current liabilities 85,551 — 85,551 Long term liabilities: Long-term debt 1,945 — 1,945 Deferred income taxes 15,706 — 15,706 Other long-term liabilities 2,534 420 2,954 Total liabilities 105,736 420 106,156 Stockholders’ equity: Common stock – $0.01 par value, 100,000,000 authorized, and 32,801,896 and 31,976,661 outstanding at December 31, 2015 and December 31, 2014, respectively 320 — 320 Additional paid-in capital 352,982 980 353,962 Accumulated other comprehensive income (loss) (3,374 ) — (3,374 ) Accumulated deficit (74,176 ) (2,930 ) (77,106 ) Total stockholders’ equity 275,752 (1,950 ) 273,802 Total liabilities and stockholders’ equity $ 381,488 $ (1,530 ) $ 379,958 Consolidated Statements of Cash Flows (in thousands) Year ended December 31, As reported Adjustments As restated Cash flows from operating activities Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 9,524 — 9,524 Stock-based compensation 2,683 — 2,683 Equity in net income of joint ventures (3,987 ) — (3,987 ) Dividends from unconsolidated joint ventures 1,511 — 1,511 Gain on previously held equity interest — — — Deferred income taxes, net (26,242 ) 2,510 (23,732 ) Other (200 ) (980 ) (1,180 ) Changes in operating assets and liabilities, net of effect of acquisition: Accounts receivable (16,442 ) — (16,442 ) Inventories, net (1,713 ) — (1,713 ) Prepaid expenses and other current assets 2,171 — 2,171 Due from related party (1,208 ) — (1,208 ) Accounts payable and other accrued liabilities 17,201 420 17,621 Net cash provided by (used in) operating activities 23,179 (980 ) 22,199 Cash flows from investing activities Capital expenditures (4,242 ) — (4,242 ) Acquisition of business, net of cash acquired (86,467 ) — (86,467 ) Purchases of investments (87,171 ) — (87,171 ) Sale of investments 181,352 — 181,352 Purchase of product rights (4,404 ) — (4,404 ) Other — — — Net cash (used in) provided by investing activities (932 ) — (932 ) Cash flows from financing activities Increase (reduction) in short-term borrowings 1,152 — 1,152 Repayment of long-term debt (10,420 ) — (10,420 ) Proceeds from issuance of common stock, net of issuance costs 1,023 — 1,023 Payment of deferred financing costs (285 ) — (285 ) Excess tax benefits on stock option exercises — 980 980 Net cash (used in) provided by financing activities (8,530 ) 980 (7,550 ) Effect of exchange rate movements in cash (416 ) — (416 ) Net increase (decrease) in cash and cash equivalents 13,301 — 13,301 Cash and cash equivalents, at beginning of period 42,332 — 42,332 Cash and cash equivalents, at end of period $ 55,633 $ — $ 55,633 Supplemental disclosure of cash flow information Acquisition of property, plant and equipment in accounts payable $ 934 $ — $ 934 Cash paid for interest $ 1,361 $ — $ 1,361 Cash paid for taxes $ 2,555 $ — $ 2,555

Assets Held for Sale

Assets Held for Sale	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Assets Held for Sale	Note 3. Assets Held for Sale: On December 29, 2015, the Board of Directors authorized us to proceed with a sale of all of the Company’s interests in SCP. As of December 31, 2015, SCP is reported as held for sale in our Consolidated Balance Sheet. In conjunction with the decision to proceed with the sale of SCP we assessed the long-lived assets for impairment and determined their carrying value was higher than the fair value less cost to sell the related assets. Fair value was determined based on a level 3 measurement, for which limited market data existed. As such, we recorded an impairment charge of $45,158 in the year ended December 31, 2015. This charge is included in Impairment of SCP long-lived assets in the Consolidated Statement of Operations. Condensed balance sheet information of SCP as of December 31, 2015 is presented below. December 31, Condensed balance sheet information Accounts receivable, net 8 Inventories, net 3,529 Property, plant, and equipment, net 500 Other assets 589 Total assets of SCP as held for sale in the Balance Sheet $ 4,626 Accounts payable $ 722 Accrued liabilities 1,876 Other liabilities 312 Total liabilities of SCP as held for sale in the Balance Sheet $ 2,910 On February 3, 2016, the Company entered into a Share Purchase Agreement whereby Hong Kong King-Friend Pharmaceutical Co., Ltd., a subsidiary of Nanjing King-Friend Pharmaceutical Co., Ltd., (“NKF”) will acquire 100% of the outstanding shares of SCP in exchange for $500. We expect this transaction to close in the second quarter of 2016, at which time SCP will cease to be a subsidiary of the Company. In connection with the closing of the transaction, we may incur additional charges related to employee severance, cumulative currency translation adjustments or transferred working capital that is not recovered through operations subsequent to December 31, 2015.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Sagent Agila LLC
Acquisitions	Note 4. Acquisitions: Omega Acquisition On October 1, 2014, we, through our wholly-owned Canadian subsidiary, Sagent Acquisition Corp., entered into a Share Purchase Agreement to acquire all of the issued and outstanding shares of the capital stock of Omega for C$92,768 ($82,693), after accounting for net post-closing adjustments of C$191 ($170). In September 2015, we finalized the post-closing adjustments resulting in a reduction of total purchase consideration of C$241 ($215). Under the acquisition method of accounting, the total consideration transferred for the 100% equity interest has been preliminarily allocated to the net identifiable assets based on the estimated fair value at the date of acquisition. Except as it relates to inventory, property, plant and equipment, and intangible assets, the carrying value of assets and liabilities in Omega’s historical financial statements have been determined to approximate fair value due to their short term nature. The excess of the consideration transferred over the net identifiable assets, after considering the tax effects of temporary differences due to the fair value adjustments, has been recorded as goodwill as of the acquisition date. The goodwill associated with this acquisition has all been assigned to the Omega operating segment; none of the goodwill is tax-deductible. The acquisition date fair value transferred for the purchase of Omega is as follows: (in thousands) Cash $ 82,863 Net working capital adjustments receivable from the sellers (170 ) Total purchase consideration $ 82,693 The fair value of identifiable assets acquired and liabilities assumed for the Omega acquisition is shown in the table below: (in thousands) Cash $ 3 Accounts receivable, net 3,419 Inventory 14,014 Prepaid and other current assets 1,295 Property, plant and equipment 14,307 Definite-lived intangible assets 49,918 In-process research and development 7,666 Goodwill 22,842 Accounts payable (2,410 ) Other accrued liabilities (4,090 ) Long-term debt and notes payable (7,095 ) Deferred income tax liabilities (17,176 ) Total allocation of fair value $ 82,693 We recorded goodwill of $22,842 due to synergies achieved by having control over the products and manufacturing at Omega. We increased goodwill in 2015 by $649 to reflect the final allocation of in-process research and development and post-closing adjustments. Omega’s revenues of $8,561 and losses of $2,126 from the date of acquisition are included in the Company’s consolidated results for the year ended December 31, 2014. The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if the Omega acquisition had taken place on January 1, 2014. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date. Year Ended 2014 (As Restated) Condensed statement of operations information Net revenues $ 312,853 Net income 35,462 Diluted income per common share $ 1.08 Remaining equity interest of SCP On April 30, 2013, we entered into a Share Purchase Agreement with Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. (“CKT”) to acquire CKT’s 50% equity interest in KSCP for $25,000, payable in installments through September 2015. The SCP Acquisition closed on June 4, 2013, following approval by the Chengdu Hi-Tech Industrial Development Zone Bureau of Investment Services. Concurrent with the closing of the SCP Acquisition, we paid $10,000 of the aggregate purchase consideration, and recorded a liability of $13,836 representing the fair value of our future payments as of the acquisition date to CKT under the terms of the Share Purchase Agreement. In December 2013 and September 2014, we paid $2,500 and $3,500, respectively, of the installment payment obligation. As of December 31, 2014, a final installment payment remained of $9,000, which was paid in September 2015. The SCP Acquisition was financed with cash and short term investments. The SCP Acquisition provided us with full control of the SCP manufacturing facility and served our long term strategic goals of additional investment in product development and vertically integrated capacity expansion. As a result of the SCP Acquisition, we remeasured the previously held equity interest in KSCP to fair value, resulting in a gain of $2,936 reported as gain on previously held equity interest in the consolidated statements of operations. The gain includes $2,782 reclassified from accumulated other comprehensive income (loss), and previously recorded as currency translation adjustments. Both the gain on previously held equity interest and the fair value of the non-controlling interest in SCP that we acquired were based on an asset approach valuation method. Acquisition related costs of $479 were recognized as product development expenses. The acquisition date fair value transferred for the purchase of SCP is as follows: (in thousands) Cash $ 10,000 Present value of remaining purchase consideration 13,836 Previously held equity interest 15,949 Gain on remeasurement of previously held equity interest in KSCP 154 Total purchase consideration $ 39,939 The fair value of identifiable assets acquired and liabilities assumed for the SCP Acquisition is shown in the table below: (in thousands) Goodwill $ 6,038 Acquired tangible assets, net of assumed liabilities 33,901 Total allocation of fair value $ 39,939 The net tangible assets acquired consisted primarily of cash of $2,704, inventory of $2,396, prepaid assets of $196, and property, plant and equipment of $56,654, net of assumed liabilities, primarily long term bank loans of $19,095 and accrued compensation and other liabilities of $8,954. We recorded goodwill of $6,038 due to the synergies achieved by having control over the products and manufacturing at the SCP facility. The goodwill associated with this acquisition has all been assigned to the Sagent US operating segment; none of the goodwill is tax-deductible. SCP’s revenues of $344 and losses of $6,137 from the date of acquisition are included in the company’s consolidated results for the year ended December 31, 2013 from the date of acquisition. The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if the SCP acquisition had taken place on January 1, 2013. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date. Year Ended December 31, 2013 Condensed statement of operations information Net revenues $ 244,750 Net income 25,881 Diluted income per common share $ 0.86 Product rights acquisitions On August 5, 2015, we entered into and closed an agreement with Mustafa Nevzat Ilac Sanayii A.S., a subsidiary of Amgen, Inc., (“MN”) to acquire the rights to three products: Methylprednsilone Sodium Succinate, Vecuronium and Pamidronate Disodium. The total fair value of consideration transferred was $3,000, consisting of cash. The product rights have been recognized in our Sagent US segment. The transaction was accounted for as a purchase of a business. The acquisition of these three products provides us with full control of and access to the product rights. The acquisition was financed with cash. Acquisition related costs related to this transaction were nominal. The weighted average life of these three acquired products rights is approximately 84 months. The estimated fair value of identifiable assets acquired for these product rights is shown in the table below: (in thousands) Definite-lived intangible assets $ 3,000 Total allocation of fair value $ 3,000 On December 19, 2014, we entered into and closed an agreement with Mylan to acquire three products rights, Rocuronium, Clindamycin, and Cisatracurium, owned by Sagent Agila. The total fair value of consideration transferred was $1,760, consisting of $1,155 of cash and $605 of contingent consideration. Sagent Agila deconsolidated its ownership in the product rights, recognizing a gain on sale of $1,760, which the joint venture partners shared through their equity interests in Sagent Agila. The products rights have been recognized in our Sagent US segment. We estimated the fair value of the contingent consideration to be $605 using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the Cisatracurium product approval date. The transaction was accounted for as a purchase of a business, and consequently, results of operations reflect the new basis of accounting from the date of the acquisition. The acquisition of these three products provides us with full control of the product rights and enhanced profitability, as we will no longer be required to share the profitability with our joint venture partner. The acquisition was financed with cash. Acquisition related costs related to this transaction were nominal. The estimated fair value of identifiable assets acquired and liabilities assumed for Rocuronium, Clindamycin, and Cisatracurium is shown in the table below: (in thousands) Definite-lived intangible assets $ 720 In-process research and development 1,040 Total allocation of fair value $ 1,760 On August 30, 2013, we entered into an agreement with Mylan to acquire two products rights, Mesna and Acetylcysteine, owned by Sagent Agila. The acquisition closed on December 12, 2013, following the completion of Mylan’s acquisition of Agila from Strides. Under the terms of the agreement, we acquired the product rights from Sagent Agila. The total fair value of consideration transferred was $3,400, consisting of $3,200 of cash and $200 of contingent consideration. Sagent Agila deconsolidated its ownership in the product rights, recognizing a gain of $3,400, which the joint venture partners shared through their equity interests in Sagent Agila. The product rights have been recognized in our Sagent US segment. We estimated the fair value of the contingent consideration to be $200 using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the Acetylcysteine product approval date. The transaction was accounted for as a purchase of a business, and consequently, results of operations reflect the new basis of accounting from the date of the acquisition. The acquisition of these two products provides us with full control of the product rights and enhanced profitability, as we will no longer be required to share the profitability with our joint venture partner. The acquisition was financed with cash. Acquisition related costs related to this transaction were nominal. The fair value of identifiable assets acquired and liabilities assumed for Mesna and Acetylcysteine is shown in the table below: (in thousands) Definite-lived intangible asset $ 2,180 In-process research and development 1,220 Total allocation of fair value $ 3,400

Investments

Investments	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments	Note 5. Investments Our investments at December 31, 2015 were comprised of the following: Cost basis Unrealized gains Unrealized Carrying value Cash and equivalents Short term investments Assets Cash $ 15,124 $ — $ — $ 15,124 $ 15,124 $ — Money market funds 13,838 — — 13,838 13,838 — Corporate bonds and notes 20,128 — (68 ) 20,060 — 20,060 $ 49,090 $ — $ (68 ) $ 49,022 $ 28,962 $ 20,060 Our investments at December 31, 2014 were comprised of the following: Cost basis Unrealized Unrealized Carrying Cash and Short term Assets Cash $ 42,494 $ — $ — $ 42,494 $ 42,494 $ — Money market funds 13,139 — — 13,139 13,139 — Corporate bonds and notes 18,513 1 (41 ) 18,473 — 18,473 $ 74,146 $ 1 $ (41 ) $ 74,106 $ 55,633 $ 18,473 Investments with continuous unrealized losses for less than twelve months and their related fair values were as follows: December 31, 2015 December 31, 2014 Fair value Unrealized Fair value Unrealized Corporate bonds and notes 20,060 (68 ) 16,468 (41 ) Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. Because we do not intend to sell these investments, and it is not more likely than not that we will be required to sell our investments before recovery of their amortized cost basis, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2015 or 2014. The original cost and estimated current fair value of our fixed-income securities as of December 31, 2015 are set forth below. Cost basis Estimated fair Due in one year or less $ 9,417 $ 9,406 Between one and five years 10,710 10,654

Accounts Receivable and Concent

Accounts Receivable and Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Accounts Receivable and Concentration of Credit Risk	Note 6. Accounts Receivable and Concentration of Credit Risk We typically establish multi-year contractual agreements with GPOs and individual hospital groups to offer our products to end-user customers. As is common in the pharmaceutical industry, a significant amount of our pharmaceutical products are sold to end users under these GPO contracts through a relatively small number of drug wholesalers. Three wholesalers collectively represented approximately 78%, 85%, and 84% of our consolidated net revenue in 2015, 2014 and 2013, respectively, and represented approximately 89% and 90% of our consolidated accounts receivable at December 31, 2015 and 2014, respectively. To help control our credit exposure, we routinely monitor the creditworthiness of customers, review outstanding customer balances, and record allowances for bad debts as necessary. Historical credit loss has not been significant. We had a reserve of $43 and $1,433 for bad debts as of December 31, 2015 and 2014, respectively. We do not require collateral.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Note 7. Inventories Inventories at December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Approved Pending Inventory Approved Pending Inventory Raw materials $ 4,855 2,800 7,655 $ 10,203 $ 2,848 $ 13,051 Work in process 433 — 433 2,012 — 2,012 Finished goods 73,365 — 73,365 49,960 — 49,960 Inventory reserve (5,000 ) — (5,000 ) (3,242 ) — (3,242 ) $ 73,653 2,800 76,453 $ 58,933 $ 2,848 $ 61,781 We have $2,800 of pre-launch inventory, predominately active pharmaceutical ingredient related to Iron Sucrose, recorded in raw material inventory as of December 31, 2015. In December 2015, we received a Complete Response Letter (“CRL”) from the US FDA related to our ANDA for Iron Sucrose regarding our pending ANDA. We are evaluating the CRL to determine our response and the impact that the CRL may have on the ultimate commercialization of the product. Depending on the outcome of the CRL response, we may change our plans regarding this inventory, which may result in our not realizing its full value. We expect the outcome of this process to be resolved in 2016.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Note 8. Property, plant and equipment Property, plant and equipment at December 31, 2015 and 2014 were as follows: December 31, 2015 2014 Land and land improvements $ 1,102 $ 3,519 Buildings and improvements 6,713 26,605 Machinery, equipment, furniture and fixtures, and software 9,233 42,124 Construction in process 6,535 6,175 23,583 78,423 Less: accumulated depreciation (3,822 ) (7,270 ) $ 19,761 $ 71,153 Depreciation expense was $5,815, $4,355, and $1,620 in the years ended December 31, 2015, 2014 and 2013, respectively. In 2014, we acquired C$16,050 ($14,307) of property plant and equipment in connection with the Omega acquisition.

Investment in Sagent Agila

Investment in Sagent Agila	12 Months Ended
	Dec. 31, 2015
Sagent Agila LLC
Investment in Sagent Agila	Note 9. Investment in Sagent Agila We account for our 50% interest in Sagent Agila under the equity method of accounting. Under the equity method of accounting, our share of income or loss was recorded as “equity in net income of joint ventures” in the consolidated statements of operations. Changes in the carrying value of Sagent Agila consist of the following: December 31, 2015 2014 Investment in Sagent Agila at beginning of year $ 4,539 $ 2,063 Equity in net income of Sagent Agila 2,569 3,987 Dividend paid — (1,511 ) Investment in Sagent Agila at end of year $ 7,108 $ 4,539 Condensed statement of operations and balance sheet information of Sagent Agila is presented below. All amounts are presented in accordance with accounting principles generally accepted in the United States. Year Ended December 31, 2015 2014 2013 Condensed statement of operations information Net revenues $ 9,063 $ 8,093 $ 16,927 Gross profit 5,140 6,321 5,454 Net income 5,138 7,975 8,440 December 31, 2015 2014 Condensed balance sheet information Current assets $ 17,036 $ 11,333 Noncurrent assets 303 360 Total assets $ 17,339 $ 11,693 Current liabilities $ 3,144 $ 2,636 Long-term liabilities — — Stockholders’ equity 14,195 9,057 Total liabilities and stockholders’ equity $ 17,339 $ 11,693

Goodwill and Intangible assets,

Goodwill and Intangible assets, net	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible assets, net	Note 10. Goodwill and Intangible assets, net Goodwill by reportable segment at December 31, 2015 and 2014 was as follows: 2015 2014 Sagent US $ 6,038 $ 6,038 Omega 19,146 22,117 Goodwill $ 25,184 $ 28,155 The decrease in goodwill during 2015 reflects a $3,620 reduction related to the Omega acquisition due to foreign currency translation impact and a $649 increase for final post-closing adjustments, consisting of an $864 increase following the final purchase accounting allocation to in-process research and development and a $215 reduction following the final post-closing working capital adjustment. The increase in goodwill for 2014 reflects $22,842 related to the Omega acquisition less $725 due to foreign currency translation impact. There were no reductions of goodwill relating to impairments. Intangible assets at December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Gross carrying Accumulated Intangible Gross carrying Accumulated Intangible Product licensing rights $ 4,533 (2,998 ) 1,535 $ 4,707 $ (2,878 ) $ 1,829 Product development rights 2,890 — 2,890 4,191 — 4,191 Purchased product rights and other 46,238 (5,087 ) 41,151 51,245 (1,375 ) 49,870 Total definite-lived intangible assets 53,661 (8,085 ) 45,576 60,143 (4,253 ) 55,890 In-process research and development (IPR&D) 7,590 — 7,590 9,685 — 9,685 Total intangible assets $ 61,251 $ (8,085 ) $ 53,166 $ 69,828 $ (4,253 ) $ 65,575 Movements in intangible assets were due to the following: 2015 Product Product Purchased IPR&D Balance at January 1 $ 1,829 $ 4,191 $ 49,870 $ 9,685 Acquisition of product rights 100 1,607 3,000 (864 ) Amortization (394 ) (2,908 ) (4,183 ) — Foreign currency movements — — (7,536 ) (1,231 ) Balance at December 31 $ 1,535 $ 2,890 $ 41,151 $ 7,590 2014 Product Product Purchased IPR&D Balance at January 1 $ 1,690 $ 3,252 $ 2,164 $ 1,220 Acquisition of product rights 946 2,576 — — Sagent Agila product acquisitions — — 720 1,040 Omega acquisition — — 49,918 7,666 Amortization (807 ) (1,637 ) (1,380 ) — Foreign currency movements — (1,552 ) (241 ) Balance at December 31 $ 1,829 $ 4,191 $ 49,870 $ 9,685 Amortization expense related to our product licensing rights was $394, $807, and $529 for the years ended December 31, 2015, 2014 and 2013, respectively. Amortization expense related to our product development rights was $2,908, $1,637, and $3,980 for the years ended December 31, 2015, 2014 and 2013, respectively. The weighted-average period prior to the next extension or renewal for the 21 products comprising our product licensing rights intangible asset was 53 months and the weighted-average remaining life of our purchased product rights and other definite-lived intangibles was 110 months at December 31, 2015. We currently estimate amortization expense over each of the next five years as follows: Amortization For the year ending December 31, 2016 $ 7,132 2017 4,223 2018 4,192 2019 4,121 2020 3,971

Accrued liabilities

Accrued liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued liabilities	Note 11. Accrued liabilities Accrued liabilities at December 31, 2015 and 2014 were as follows: December 31, 2015 2014 Payroll and employee benefits $ 6,512 $ 9,329 Sales and marketing 7,308 6,964 Taxes payable 131 1,040 Other accrued liabilities 1,755 2,013 $ 15,706 $ 19,346

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Note 12. Debt JPMorgan Chase Revolving Credit Loan Facility On October 31, 2014, we entered into a credit agreement with JPMorgan Chase Bank, N.A., (the “Chase Agreement”). The Chase Agreement provides for an $80,000 asset based revolving credit loan facility, with availability subject to a borrowing base consisting of eligible cash, short-term investments, accounts receivable and inventory and the satisfaction of conditions precedent specified in the Chase Agreement. The Chase Agreement provides for an accordion feature, whereby we may increase the revolving commitment up to an additional $25,000, subject to certain customary terms and conditions, including pro-forma compliance with a fixed charge coverage ratio (as defined in the Chase Agreement) of 1.00 to 1.00. The Chase Agreement matures on October 31, 2019, at which time all amounts outstanding will be due and payable. Borrowings under the Chase Agreement may be used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to, at our option, either a Eurodollar rate plus 2.00% per annum or an alternative base rate plus 1.00% per annum. We also incur a commitment fee on undrawn amounts equal to 0.25% per annum. The Chase Agreement was guaranteed by our parent company at the time of closing and is secured by a lien on substantially all of our parent company and our principal domestic subsidiary’s assets and any future domestic subsidiary’s guarantor’s assets. The Chase Agreement includes customary covenants and also imposes a financial covenant requiring compliance with a minimum fixed charge coverage ratio of 1.00 to 1.00 during certain covenant testing times triggered if availability under the Chase Agreement is below the greater of 10% of the revolving commitment and $8,000. As of December 31, 2015, there were no borrowings outstanding under our Chase Agreement, and we were in compliance with all covenants under this loan agreement. Total availability under our Chase revolving loan facility was $79.9 million at December 31, 2015, which is subject to adjustment on a monthly basis under our borrowing base calculation. On January 7, 2016, we amended and restated our Chase Agreement (the “Amended Chase Agreement”) by adding a Canadian tranche and joining Omega as a borrower. The Amended Chase Agreement adds a C$30.0 million term loan (including a delayed draw term loan) to fund, among other things, Omega’s construction of a facility in Quebec. The Amended Chase Agreement also adds a C$10.0 million revolving facility sublimit to the existing revolving facility, with the total revolving commitment amount remaining at $80.0 million. The applicable margins for the Canadian prime rate and CDOR revolving loans are the same as the base rate and Eurodollar rates for the U.S. revolving loans at 1.00% and 2.00%, respectively. The margins for the Canadian term loans are 1.25% and 2.25% for Canadian prime rate and CDOR, respectively. The commitment fee rate remains 0.25%. The fixed charge coverage ratio remains at 1.00x. The Canadian term loans are to be repaid in certain increments pursuant to the Amended Chase Agreement as the facility in Quebec is completed. Silicon Valley Bank Loan and Security Agreement In February 2012, we entered into a Loan and Security Agreement (the “SVB Agreement”) with Silicon Valley Bank (“SVB”). The SVB Agreement provided for a $40,000 asset based revolving loan facility, with availability subject to a borrowing base consisting of eligible accounts receivable and inventory and the satisfaction of conditions precedent specified in the SVB Agreement. The SVB Agreement matured on February 13, 2016, at which time all outstanding amounts will become due and payable. Borrowings under the SVB Agreement could have been used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to, at our option, either a Eurodollar rate plus 2.50% per annum or an alternative base rate plus 1.50% per annum. We also pay a commitment fee on undrawn amounts equal to 0.30% per annum. The SVB Agreement contains various customary affirmative and negative covenants. The negative covenants restrict our ability to, among other things, incur additional indebtedness, create or permit to exist liens, make certain investments, dividends and other payments in respect of capital stock, sell assets or otherwise dispose of our property, change our lines of business, or enter into a merger or acquisition, in each case, subject to thresholds and exceptions as set forth in the SVB Agreement. The financial covenants in the SVB Agreement are limited to maintenance of a minimum adjusted quick ratio and a minimum free cash flow. The SVB Agreement also contains customary events of default, including non-payment of principal, interest and other fees after stated grace periods, violations of covenants, material inaccuracy of representations and warranties, certain bankruptcy and liquidation events, certain material judgments and attachment events, cross-default to other debt in excess of a specified amount and material agreements, failure to maintain certain material governmental approvals, and actual or asserted invalidity of subordination terms, guarantees and collateral, in each case, subject to grace periods, thresholds and exceptions as set forth in the SVB Agreement. On September 23, 2013, we entered into a Second Loan Modification Agreement to the SVB Agreement with SVB (the “Modification”). The Modification altered the calculation methodology of the borrowing base that is used to determine our borrowing availability and the covenant for the Adjusted Quick Ratio tested at the end of each month and eliminated the covenant to maintain a specified level of free cash flow in quarters where we maintain eligible cash balances of $30 million or greater. We did not amend the term, the maximum availability, or the interest rate applicable to the amounts drawn under the SVB Agreement. Concurrent with entering the Chase Agreement, we terminated our prior revolving loan facility under the SVB Agreement, and repaid certain associated fees. Included with the fees was $1,050 of early termination fees that had previously been deferred by SVB as part of entering into the SVB Agreement in February 2012. This amount is included within interest expense in the consolidated statement of operations for the year ended December 31, 2014. Concurrent with the repayment and termination of the SVB Agreement, all liens and security interests against our property that secured the obligations under our prior revolving loan facility were released and discharged. Credit facilities acquired under the SCP Acquisition In connection with the acquisition of the remaining 50% equity interest in SCP, we assumed two loan contracts with the Agricultural Bank of China Ltd. in the amount of RMB 37,000 ($6,069) and RMB 83,000 ($13,613) originally entered into in June 2011 and August 2010, respectively, (the “ABC Loans”) each with a five year term. Amounts outstanding under the ABC Loans bear an interest rate equal to the benchmark lending interest rate published by the People’s Bank of China. During the term of the loan, the rate is subject to adjustment every three months. The ABC Loans are secured by the property, plant and equipment of SCP. As of December 31, 2013, RMB 63,000 ($10,333) was outstanding under the ABC Loans, at an interest rate of 6.00% per annum. As the interest rate resets on a quarterly basis, the fair value of our long-term debt approximates its carrying value. Repayment will be accelerated if the liabilities to assets ratio exceed 70% and 80% during the term of the RMB 37,000 and RMB 83,000 credit facilities, respectively, or if our SCP subsidiary is unable to achieve 50% of its projected revenues when it commences commercial activities. On January 2, 2014, we repaid in full the then-outstanding balance of the ABC Loans, totaling RMB 63.0 million ($10.3 million). Upon prepayment of the ABC Loans, the loan contracts were terminated. No early termination fees were incurred as part of the prepayment of the ABC Loans. Credit facilities acquired under the Omega acquisition In connection with the acquisition of Omega on October 1, 2014, we assumed a series of credit facilities and mortgages with the National Bank of Canada (“NBC”) and the Business Development Bank of Canada (“BDC”), as described below. Omega has an authorized credit facility (the “Omega operating credit facility”) in the amount of C$8,200 ($7,309) with the NBC. The Omega operating credit facility can be utilized in the form of floating-rate advances for an amount not exceeding C$7,000 ($6,239 as of the acquisition date) and advances in the form of letters of guarantee or letters of credit, within that limit for an amount not exceeding C$2,000 ($1,782 as of the acquisition date). The Omega operating credit facility can also be utilized in the form of advances to cover Omega’s currency risk for an amount not to exceed C$1,200 ($1,070 as of the acquisition date). On October 1, 2014, the Omega operating credit facility had floating-rate advances in the amount of C$1,530 ($1,364) bearing interest at the lender’s prime rate plus 0.50%, (or an effective rate of 3.5%) which we assumed as part of the acquisition. In July 2014, Omega obtained a C$3,000 demand loan (the “Omega demand loan”), from the NBC bearing interest at the prime rate of the lender, plus a premium of 1.75% (effective rate 4.75%). The Omega demand loan is secured by all of the assets of Omega for C$3,000 plus an additional security interest of 20% of this amount, bearing interest at 4.75% per annum and matured in November 2014. We assumed the Omega demand loan ($2,674 as of the acquisition date) in connection with the acquisition and subsequently extended the maturity date to January 2015. The Omega operating credit facility and the Omega demand loan are secured by a first ranking security interest in the amount of C$8,250 ($7,354 as of the acquisition date) in Omega’s inventories, trade receivables and on the intellectual property of Omega, present and future. Omega also had C$267 ($238) outstanding on a decreasing revolving credit facility with the NBC (the “Omega decreasing revolving credit facility”) bearing interest at the prime rate of the lender, plus 1.0% (or an effective rate equal to 4.0%). The Omega decreasing revolving credit facility is secured by a first ranking security interest of C$1,000 ($891 as of the acquisition date) on the equipment, tooling and office furniture financed by the credit facility. The Omega credit facilities are subject to certain restrictions, including the obligation to maintain certain financial ratios. As of October 1, 2014, Omega had not met certain financial ratios. As a result, the Omega decreasing revolving credit facility was classified as a current liability as of the acquisition date. In January 2015, we paid off all amounts outstanding under the Omega operating credit facility, the Omega demand loan and the Omega decreasing revolving credit facility with available cash on hand. As a result, all amounts outstanding under these instruments were classified as current liabilities at December 31, 2014. In addition to the above, Omega had five mortgage loans with the BDC (collectively the “Omega mortgages”) which we assumed in connection with the acquisition. The Omega mortgages, which require monthly installments and which are secured by specific Omega buildings and equipment, range in amount from C$70 to C$1,250 ($62 to $1,114 as of the acquisition date) and bear interest at the lender’s prime rate (5% as of the acquisition date) plus a premium ranging from 0%—1.5%. The carrying value of the mortgages approximates fair value. The Omega mortgages mature at various times from August 2019 through November 2036. In January 2016, in connection with entering the Amended Chase Agreement, we repaid the Omega mortgages in full, and refinanced them under the Chase term loan. As a result, all amounts outstanding under these instruments are classified as long term liabilities at December 31, 2015. Debt maturities by year are as follows: December 31, Amount 2016 $ — 2017 — 2018 — 2019 1,623 2020 — 2021 and thereafter — Total long-term debt 1,623 Less: Current maturities of long-term debt — Long-term portion of long-debt $ 1,623

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 13. Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 consisted of the following: Total fair value Quoted prices in Significant other Significant Assets Money market funds $ 13,838 $ 13,838 — — Corporate bonds and notes 20,060 — $ 20,060 — Commercial paper — — — — Short-term investments $ 33,898 $ 13,838 $ 20,060 — Total assets $ 33,898 $ 13,838 $ 20,060 — Liabilities Contingent purchase consideration $ 50 — — $ 50 The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity. Assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 consisted of the following: Total fair value Quoted prices in Significant other Significant Assets Money market funds $ 13,139 $ 13,139 $ — $ — Corporate bonds and notes 18,513 — 18,513 — Commercial paper — — — — Short-term investments $ 18,513 $ — $ 18,513 $ — Total assets $ 31,652 $ 13,139 $ 18,513 $ — Liabilities Contingent purchase consideration $ 605 $ — $ — $ 605 During the year ended December 31, 2015, changes in the fair value of our contingent purchase consideration measured using significant unobservable inputs (Level 3), were comprised of the following: Year ended Balance at beginning of period $ 605 Issuance of contingent purchase consideration — Change in fair value of contingent purchase consideration (555 ) Payment of contingent purchase consideration — Balance at end of period $ 50 The change in fair value of contingent purchase consideration of $555 relates to the likelihood of seller meeting the contractual FDA approval timeline related to the December 2014 acquisition of Cisatracurium from Sagent Agila LLC.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Postemployment Benefits [Abstract]
Employee Benefit Plan	Note 14. Employee Benefit Plan We sponsor a 401(k) defined-contribution plan (the “401(k) Plan”) covering substantially all eligible US employees. Employee contributions to the 401(k) Plan are voluntary. We contribute an amount equal to 50% of a covered employee’s eligible contribution up to 6% of a participant’s compensation. Employer contributions vest over a period of three years. Participants’ contributions are limited to their annual tax deferred contribution limit as allowed by the Internal Revenue Service. The Company’s total matching contributions to the 401(k) Plan were $430, $391, and $338 for years ended December 31, 2015, 2014 and 2013, respectively. We may contribute additional amounts to the 401(k) Plan at our discretion. Discretionary employer contributions vest over the same three-year period. We made no discretionary contributions to the 401(k) Plan during the three-year period ended December 31, 2015.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	Note 15. Stockholders’ Equity Common Stock We are authorized to issue 100,000,000 shares of common stock as of both December 31, 2015 and 2014. We have reserved 5,892,670 shares at December 31, 2015 and 2014, for the issuance of common stock upon the exercise of outstanding stock options. On September 16, 2013, we completed a registered equity offering, issuing 3,542,470 new shares of our common stock at $21.25 per share in exchange for total consideration of $75,277. We received proceeds from the offering, net of the underwriting discount and expenses, of $70,580.

Accumulated Comprehensive Incom

Accumulated Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Accumulated Comprehensive Income (Loss)	Note 16. Accumulated Comprehensive Income (Loss) Accumulated comprehensive income (loss) at December 31, 2015, 2014 and 2013 is comprised of the following: December 31, 2015 2014 2013 Currency translation adjustment, net of tax $ (17,414 ) $ (3,334 ) $ 496 Unrealized gain (loss) on available for sale securities, net of tax (68 ) (40 ) (9 ) $ (17,482 ) $ (3,374 ) $ 487 The following table summarizes the changes in balances of each component of accumulated other comprehensive income, net of tax as of December 31, 2015. Currency Unrealized gains Total Balance as of December 31, 2014 $ (3,334 ) $ (40 ) $ (3,374 ) Other comprehensive income (loss) before reclassifications (14,080 ) (28 ) (14,108 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive loss (14,080 ) (28 ) (14,108 ) Balance as of December 31, 2015 $ (17,414 ) (68 ) (17,482 ) Currency Unrealized gains Total Balance as of December 31, 2013 $ 496 $ (9 ) $ 487 Other comprehensive income (loss) before reclassifications (3,830 ) (31 ) (3,861 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive loss (3,830 ) (31 ) (3,861 ) Balance as of December 31, 2014 $ (3,334 ) $ (40 ) $ (3,374 ) Currency Unrealized gains Total Balance as of December 31, 2012 $ 2,488 $ 12 $ 2,500 Other comprehensive income (loss) before reclassifications 790 (21 ) 769 Amounts reclassified from accumulated other comprehensive income (loss) (2,782 ) — (2,782 ) Net current-period other comprehensive loss (1,992 ) (21 ) (2,013 ) Balance as of December 31, 2013 $ 496 $ (9 ) $ 487 No amounts were reclassified out of accumulated other comprehensive income for the years ended December 31, 2015 and 2014. The table below presents the amounts reclassified out of each component of accumulated other comprehensive income for the year ended December 31, 2013. Type of reclassification Amount Affected line item in the condensed consolidated statement of operations Currency translation adjustment – reclassification of cumulative currency translation gain $ 2,782 Gain on previously held equity interest Total reclassification for the year ended December 31, 2013, net of tax $ 2,782

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Note 17. Earnings Per Share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period. Because of their anti-dilutive effect, 1,859,247, 705,150, and 1,194,717 of common share equivalents, comprised of unexercised stock options, have been excluded from the diluted earnings per share calculation for the years ended December 31, 2015, 2014 and 2013, respectively. The table below presents the computation of basic and diluted earnings per share for the years ended December 31, 2015, 2014 and 2013. Year Ended December 31, 2015 2014 (Restated) 2013 Basic and dilutive numerator Net income (loss), as reported $ (21,882 ) $ 36,951 $ 29,594 Denominator Weighted average common shares outstanding – basic (in thousands) 32,439 31,882 29,213 Net effect of dilutive securities Stock options and restricted stock — 863 724 Weighted average common shares outstanding – diluted (in thousands) 32,439 32,745 29,937 Net income (loss) per common share (basic) $ (0.67 ) $ 1.16 $ 1.01 Net income (loss) per common share (diluted) $ (0.67 ) $ 1.13 $ 0.99

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 18. Stock-Based Compensation Prior to the initial public offering, we had a stock plan, the 2007 Global Share Plan (the “2007 Plan”), for key employees and nonemployees, which provided for the grant of nonqualified and incentive stock options and/or shares of restricted stock, deferred stock, and other equity awards in our common stock. Concurrent with the initial public offering, our Board adopted the 2011 Incentive Compensation Plan (the “2011 Plan”, with the 2007 Plan, the “Plans”), for employees and nonemployees, which provides for the grant of nonqualified and incentive stock options and/or shares of restricted stock, deferred stock and other equity awards in our common stock. The Board administers the Plans. A total of 2,475,184 and 4,000,000 shares are authorized under the 2007 Plan and 2011 Plan, respectively, as of December 31, 2015. At December 31, 2015, we had 417,280 shares of common stock available for grant under the 2007 Plan and 2,215,631 shares of common stock available for grant under the 2011 Plan. Stock options, exercisable for shares of our common stock, generally vest over a four-year period from the grant date and expire ten years from the grant date. The strike price of the stock options granted under the 2007 Plan is established at or above the fair value of our stock as of the grant date. The strike price of stock options granted under the 2011 Plan is established as the closing price of our stock on the business day prior to the grant date. In 2010, the Board approved an amendment to the 2007 Plan which permitted employees to exercise their stock options prior to vesting. Once purchased, we have the right to repurchase unvested stock from the employee upon termination of their services. The repurchase price is equal to the original exercise price of the option. Restricted Stock The Company measures the fair value of the restricted stock on the date of grant based on the estimated fair value of the common stock on that day. The fair value is amortized to stock-based compensation expense, net of estimated forfeitures, ratably over the vesting period. As of December 31, 2015, the total amount of unrecognized stock-based compensation related to grants of restricted stock was approximately $2,770. The Company expects to recognize this expense over an average period of approximately 29 months. The following table summarizes restricted stock activity during the year ended December 31, 2015: Restricted Weighted-Average Grant Date Fair Value Balance at January 1, 2015 128,209 $ 19.32 Granted 140,971 24.59 Vested (40,496 ) 19.42 Forfeited (48,476 ) 22.10 Balance at December 31, 2015 180,208 $ 22.91 Stock Options – Valuation Information We estimate the value of stock options on the date of grant using a Black-Scholes option pricing model. The risk-free rate of interest for the average contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is zero as we have not paid nor do we anticipate paying any dividends. For service-based awards, we used the “simplified method” described in Staff Accounting Bulletin (“SAB”) Topic 14, Share-Based Payment, Risk free interest rate Expected life Expected dividend yield Expected volatility Fair value at grant date 2015 1.74 % 6 years 0 % 52 % $ 10.92 2014 1.92 % 6 years 0 % 61 % $ 11.81 2013 1.24 % 6 years 0 % 62 % $ 9.31 Stock options outstanding that have vested and are expected to vest as of December 31, 2015, were as follows: Number of shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value (1) Vested 1,021,292 $ 12.96 5.3 4,503 Expected to vest 600,054 $ 22.27 8.5 18 Total 1,621,346 $ 16.61 6.5 4,521 (1) The Aggregate Intrinsic Value amounts represent the difference between the exercise price and $15.91, the fair value of our stock on December 31, 2015, for in-the-money options. In December 2014, we reversed $1,901 of stock compensation expense related to a performance-based award, as achievement of the performance criteria was no longer probable. Stock Option Activity The following table sets forth stock option activity for the year ended December 31, 2015: Options Outstanding Exercisable Options Number of shares Weighted-Average Exercise Price Number of shares Weighted-Average Exercise Price Outstanding at January 1, 2015 2,543,362 14.71 1,622,212 12.04 Granted 411,743 25.11 Exercised (794,528 ) 12.32 Forfeited (481,538 ) 20.93 Outstanding at December 31, 2015 1,679,039 16.61 1,021,292 12.96 As of December 31, 2013, the weighted-average remaining contractual lives of options outstanding and options exercisable were 7.2 years and 6.5 years, respectively. As of December 31, 2014, the weighted-average remaining contractual lives of options outstanding and options exercisable were 6.6 years and 5.9 years, respectively. As of December 31, 2015, the weighted-average remaining contractual lives of options outstanding and options exercisable were 6.6 years and 5.3 years, respectively. The total intrinsic value of options exercised in 2015, 2014 and 2013 was $9,169, $3,147, and $1,860, respectively. The total fair value of options vested was approximately $2,900, $3,327, and $5,036 in 2015, 2014 and 2013, respectively. As of December 31, 2015, there was $5,853 of unrecognized stock-based compensation expense related to unvested stock options, which will be recognized over a weighted-average period of 1.4 years.

Net Revenue by Product

Net Revenue by Product	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Net Revenue by Product	Note 19. Net Revenue by Product We are focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. Our anti-infective products assist in the treatment of various infections and related symptoms, our oncology products are used in the treatment of cancer and cancer-related medical problems, and our critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products, sedatives and certain allergy products. Net revenue by product category is as follows: 2015 2014 2013 Therapeutic Class Anti-Infective $ 128,517 $ 102,078 $ 90,604 Critical Care 120,157 87,143 65,612 Oncology 69,622 99,762 88,534 Total $ 318,296 $ 288,983 $ 244,750

Segment and Geographic Data

Segment and Geographic Data	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment and Geographic Data	Note 20. Segment and Geographic Data Management uses segment information to evaluate segment performance and allocate resources. Historically we have operated in a single reportable segment, the United States. Effective October 1, 2014, in connection with the Omega acquisition, we began operating in two reportable segments comprised of operations organized geographically within the United States (Sagent US segment) and Canada (Omega segment), each of which develop, source, manufacture and market generic injectable products for sale within the their respective countries. Each segment derives a significant portion of its revenues from a single class of pharmaceutical wholesale customers within that country. Management utilizes segment operating income as its measure of segment profitability. Segment and geographic data for the year ended December 31, 2014 includes the impact of Omega from the date of acquisition, October 1, 2014, through December 31, 2014. Shared costs for certain corporate functions, including but not limited to, corporate finance and legal, are included within the Sagent US segment profitability that management reviews. We use the same accounting policies for the segments as disclosed in Note 1, Summary of Significant Accounting Policies. Geographic and segment data is as follows: 2015 2014 2013 Net revenue: United States $ 286,773 $ 280,339 $ 244,272 Others 839 83 478 Sagent US segment 287,612 280,422 244,750 Canada (Omega segment) 30,684 8,561 — Total net revenue $ 318,296 288,983 244,750 2015 2014 2013 Long-lived assets: United States $ 80,947 $ 37,252 $ 17,401 China — 52,635 57,016 Sagent US segment 80,947 91,417 74,417 Canada (Omega segment) 77,193 91,553 — Total long-lived assets $ 158,140 $ 181,440 $ 74,417 2015 2014 2013 Depreciation and amortization expense: Sagent US 8,826 8,188 7,074 Omega 4,855 1,336 — Total depreciation and amortization expense $ 13,681 $ 9,524 $ 7,074 2015 2014 2013 Equity in net income of joint ventures: Sagent US $ 2,569 $ 3,987 $ 2,395 Omega — — — Total equity in net income of joint ventures $ 2,569 $ 3,987 $ 2,395 2015 2014 2013 Operating income (loss): Sagent US $ (43,769 ) $ 21,700 $ 31,380 Omega (752 ) (2,656 ) — Total operating income (loss) $ (44,521 ) $ 19,044 $ 31,380 2015 2014 2013 Interest expense: Sagent US $ 564 $ 1,979 $ 930 Omega 206 209 — Total interest expense $ 770 $ 2,188 $ 930 2015 2014 2013 Interest income and other: Sagent US $ (2,495 ) $ 375 $ 205 Omega (295 ) — — Total interest income $ (2,790 ) $ 375 $ 205 2015 2014 (Restated) 2013 Income tax provision (benefit): Sagent US $ (25,993 ) $ (20,034 ) $ 895 Omega (206 ) (739 ) — Total income tax provision (benefit) $ (26,199 ) $ (20,773 ) $ 895 2015 2014 2013 Capital expenditures: Sagent US $ (1,447 ) $ (3,510 ) $ (1,103 ) Omega (5,264 ) (732 ) — Total capital expenditures $ (6,711 ) $ (4,242 ) $ (1,103 ) 2015 2014 (Restated) 2013 Deferred tax assets: Sagent US $ 50,808 $ 23,778 $ 6 Omega — — — Total deferred tax assets $ 50,808 $ 23,778 $ 6 2015 2014 2013 Investment in joint ventures: Sagent US $ 7,108 $ 4,539 $ 2,063 Omega — — — Total investment in joint ventures $ 7,108 $ 4,539 $ 2,063 2015 2014 (Restated) 2013 Total assets: Sagent US $ 258,275 $ 272,283 $ 310,208 Omega 91,457 107,675 — Total assets $ 349,732 $ 379,958 $ 310,208

Management Transition

Management Transition	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Management Transition	Note 21. Management Transition: Throughout 2015, we incurred costs related to the transition of our senior management team, following the retirement of our founder and Chief Executive Officer and resignation of our President in March 2015, and the elimination of certain positions in the US as part of the ongoing review of our business. Costs associated with these matters, primarily severance related charges and costs associated with recruiting and retaining a new CEO totaled $5,310, were all incurred in the Sagent US reportable segment, and are reflected in the management transition caption of the consolidated statement of operations for the year ended December 31, 2015. Of the charges, $4,019 were paid during the year ended December 31, 2015. Total costs accrued within the Accounts Payable and Accrued liabilities captions of the balance sheet at December 31, 2015 were $1,291.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 22. Income Taxes: Components of income (loss) before income taxes are as follows: Year Ended December 31, 2015 2014 (Restated) 2013 Domestic $ 8,931 $ 30,200 $ 36,671 Foreign (57,012 ) (14,022 ) (6,182 ) Income (loss) before income taxes $ (48,081 ) $ 16,178 $ 30,489 Provision (benefit) for income taxes: United States federal: Current $ 20 $ 943 $ 895 Deferred (25,887 ) (21,089 ) — (25,867 ) (20,146 ) 895 State and local: Current 937 1,853 — Deferred (1,063 ) (1,740 ) — (126 ) (113 ) — Total United States (25,993 ) (22,964 ) 895 Outside United States: Current 898 205 — Deferred (1,104 ) (944 ) — Total outside United States (206 ) (739 ) — Total provision (benefit) for income taxes $ (26,199 ) $ (20,773 ) $ 895 Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and net operating loss and other tax credit carryforwards. These items are measured using the enacted tax rates applicable to the period when the differences are expected to reverse. We record a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. As of December 31, 2014, we had cumulative domestic income over the prior three years, had completed eight consecutive quarters of domestic pretax earnings, and forecasted continued domestic profitability in future periods. Accordingly, we concluded that the valuation allowance previously recorded against our domestic deferred tax assets should be released as of December 31, 2014, resulting in a net $25,308 benefit in our provision for income taxes that has been restated to $23,778, as described in Note 2. Restatement. As of December 31, 2015, we continue to be in a three year cumulative income position in the US. In connection with the decision to sell SCP in December 2015, we determined that SCP’s capital stock and the intercompany loans from our US parent company to SCP were impaired. We made tax elections to realize this value through deductions for worthless stock and bad debt. In 2015, due to the one-time permanent benefit of $30,041 related to the SCP disposition, we recorded a taxable loss in the U.S. Since, prior to 2015, we have generated significant US taxable income and are forecasting US taxable income in the future, the Company believes it is more likely than not that it will utilize the NOL generated in 2015. Domestic net operating losses and carryforwards are available for use against our consolidated federal taxable income. A summary of our remaining domestic net operating loss carryforwards, including the timing of expiry, is as follows: Year of Expiry Net Operating Loss Carryforwards 2032 300 2034 410 2036 80,325 Total $ 81,035 In addition, we have retained a full valuation allowance against our net deferred tax assets in SCP, including $14,126 recognized in 2015, given the history of losses in that entity. Net operating loss carryforwards of $48,904 related to SCP, will expire between 2016 and 2020. As of December 31, 2015, the Company’s U.S. income tax returns for 2012 and subsequent years remain subject to examination by the Internal Revenue Service (“IRS”). The Company’s 2013 income tax return is currently under examination by the IRS. State and foreign income tax returns generally have statute of limitations for periods between three and five years from the filing date. The Company is not currently under examination by any state or foreign taxing authorities. The following is a reconciliation of our income tax provision (benefit) computed at the U.S. federal statutory rate to the income tax provision (benefit) reported in the consolidated statements of operations: Year Ended December 31, 2015 2014 (Restated) 2013 Provision (benefit) at statutory rate $ (16,828 ) $ 5,662 $ 10,366 State income taxes, net of federal income tax (373 ) 1,750 230 Foreign rate differential 5,731 1,392 560 Valuation allowance 14,126 (28,672 ) (9,998 ) Worthless stock and bad debt deductions (30,041 ) — — Uncertain tax positions 101 541 — Permanent book / tax differences 164 172 (263 ) Change in tax rate 89 (1,498 ) — Other 832 (120 ) — Provision (benefit) for income taxes $ (26,199 ) $ (20,773 ) $ 895 The tax effects of temporary differences giving rise to deferred income tax assets and liabilities were: December 31, 2015 2014 (Restated) Deferred tax assets: Product development and start-up costs $ 14,005 $ 12,702 Inventory 3,539 2,493 Loss and credit carryforwards 40,358 9,664 Bad debt reserves 16 549 Accrued expenses / other 4,373 5,244 Deferred compensation 2,979 3,155 Depreciation and amortization 11,482 — Alternative minimum tax carryforwards 1,555 1,546 Total deferred tax assets $ 78,307 $ 35,353 Deferred tax liabilities: Depreciation and amortization $ (3,850 ) $ (2,799 ) Intangible assets (11,070 ) (14,351 ) Inventory (99 ) (180 ) Total deferred tax liabilities (15,019 ) (17,330 ) Net deferred tax asset 63,288 18,023 Valuation allowance (24,501 ) (9,950 ) Net deferred tax assets (liabilities) $ 38,787 $ 8,073 The Company has gross unrealized tax benefits of $3,100 arising from tax deductions for share based compensation in excess of the compensation recognized for financial reporting purposes. Realization of this excess tax benefit will occur when current taxes payable are reduced with a corresponding credit to additional paid in capital. Our unrecognized tax benefits of $726 at December 31, 2015 are included in other long-term liabilities. If we had recognized all of these benefits, the net impact on our income tax provision would have been $588. Of the net unrecognized tax benefits, approximately $120 are expected to be resolved in the next 12 months. We include accrued interest and penalties related to uncertain tax positions in our tax provision. We have accrued interest and penalties of $24 as of December 31, 2015 and $20 as of December 31, 2014. Our provision for income taxes included expense for interest and penalties of $4 in 2015 and $20 in 2014. The changes in our unrecognized tax benefits were: Year Ended December 31, 2015 2014 (Restated) 2013 Beginning of year $ 659 $ — $ — Increases from prior year tax positions 136 719 — Decreases relating to settlements with taxing authorities (85 ) (60 ) — Increases from current year positions 16 — — End of year $ 726 $ 659 $ — We classify uncertain tax positions as noncurrent income tax liabilities unless expected to be paid within one year.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 23. Commitments and Contingencies Product Development Agreements We have entered into various business agreements for the development and marketing of finished dosage form pharmaceutical products, including (i) development and supply agreements, some of which contain contingent contract payments, as well as (ii) straight-supply agreements, which may contain minimum purchase commitments. These agreements may include future payment commitments for contingent contract payments. We will be responsible for contingent contract payments based upon the occurrence of future events. Each agreement defines the triggering event of its future payment schedule, such as meeting development progress timelines, successful product testing and validation, successful clinical studies, various FDA and other regulatory approvals, and other factors as negotiated in each case. We have entered into significant development, marketing, and supply agreements with A.C.S. Dobfar S.p.a. (“Dobfar”), A.C.S. Dobfar SA-Switzerland (“Info”), and Gland Pharma Limited (“Gland”). Key terms of these agreements are set forth below. Info Under a manufacture and supply agreement with Info, Info develops, manufactures, and supplies us with presentations of levofloxacin in premix bags. We pay a transfer price for each unit of levofloxacin supplied, plus a percentage of the net profit from the sales of levofloxacin in premix bags. In addition, we have agreed to share equally with Info the cost of development activities. The initial term of the agreement expires on July 7, 2016, after which we have the option to renew the agreement for successive additional two year terms unless Info provides notice of its intent to terminate the agreement at least two years prior to its initial expiration date or the expiration date of a renewal term. In addition, we also have supply agreements or other purchase commitments with Dobfar and/or WorldGen LLC, a distributor for Dobfar covering seven currently marketed products – ampicillin, ampicillin sulbactam, cefazolin, cefepime, cefoxitin, ceftazadime and ceftriaxone – and, with Info, covering three currently marketed products – ciprofloxacin, fluconazole, and zoledronic acid bags, in both 4mg and 5mg presentations, and additional products currently under development. Gland Pursuant to our development and supply agreement with Gland, we jointly developed our heparin products with Gland, and Gland agreed to supply us heparin for sale in the U.S. market. In addition, we have agreed to use Gland as our exclusive supplier for heparin and Gland has agreed not to, directly or indirectly, sell heparin to any other person or entity that markets or makes use of or sells heparin in the U.S., subject to certain exceptions. We have agreed to pay a transfer price for each unit of heparin supplied under the agreement, plus a percentage of the net profit from the sales of heparin. In addition, each party has agreed to share the cost of development activities equally up to a specified amount. The initial term of the agreement expires in June 2016, after which, unless a third party has rights to market heparin in the U.S. as a result of our discontinuing active sales of heparin there, the agreement automatically renews for consecutive periods of one year unless either party provides notice of its intent to terminate the agreement at least 24 months prior to the desired date of termination. In addition, we also have other supply agreements with Gland covering five currently marketed products, adenosine, amiodarone, chlorothiazide, ondansetron and vancomycin, and additional products currently under initial development. Contingent contractual payments are as follows at December 31, 2015: 2016 $ 18,037 2017 4,124 2018 3,726 2019 709 2020 60 2021 and Thereafter 1,065 Total $ 27,721 Leases We have entered into various operating lease agreements for building and office space, communications, information technology equipment and software, office equipment and automobile. Total rental expense amounted to $664, $656, and $431 for the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015, total future annual minimum lease payments related to non-cancelable operating leases are as follows: 2016 $ 805 2017 501 2018 516 2019 532 2020 404 2021 and Thereafter 134 Total $ 2,892 Regulatory Matters We are subject to regulatory oversight by the FDA and other regulatory authorities with respect to the development, manufacturing and sale of our products. Failure to comply with regulatory requirements could have a significant adverse effect on our business and operations. Litigation From time to time, we are subject to claims and litigation arising in the ordinary course of business. These claims may include assertions that our products infringe existing patents and claims that the use of our products has caused personal injuries. We intend to vigorously defend any such litigation that may arise under all defenses that would be available to us. We were party to the following claim. Zoledronic Acid (Generic versions of Zometa ® ® ® Ready-to-Use ® ® 13-cv-02379, ® Pre-concentrate product On October 13, 2015, the Company and Novartis agreed to settle the Litigation. Pursuant to the terms of the settlement, we will pay Novartis $5,000 in exchange for a release of claims associated with the 241, 987 and 189 Patents pertaining to the following regulatory submissions: FDA NDA No. 203231, FDA ANDA No. 202828, FDA ANDA No. 202472 and FDA ANDA No. 091493 (collectively the Regulatory Submissions”), and acquire a license to sell the zoledronic acid products as approved by their Regulatory Submissions (excluding sales of product manufactured under FDA ANDA No.202472 after December 31, 2014) in the U.S.. Concurrent with the settlement, the Company received $1,477 from Info and Actavis, representing their collective share of the $5,000. We have determined that $1,683 of the Settlement represents a future license to sell the zoledronic acid products. This amount has been recorded within Other assets on the Consolidated Balance Sheet as of December 31, 2015, offset by the portion of the Info reimbursement, $607, related to the license period. The remaining net settlement amount of $2,447 paid to Novartis is recognized as legal settlement expense within the Consolidated Statement of Operations for the year ended December 31, 2015. At this time, there are no other proceedings of which we are aware that are considered likely to have a material adverse effect on the consolidated financial position or results of operations.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 24. Related Party Transactions: As of December 31, 2015 and 2014, respectively, we had a receivable of $2,678 and $2,156 from Sagent Agila LLC, which is expected to offset future profit-sharing payments. These amounts are classified as due from related party on the consolidated balance sheet. As of December 31, 2015 and 2014, respectively, we had a payable of $13,754 and $8,079 to Sagent Agila LLC, principally for the acquisition of inventory and amounts due under profit-sharing arrangements that are classified as due to related party on the consolidated balance sheet. During the year ended December 31, 2015 there were no distributions from Sagent Agila LLC. During the year ended December 31, 2014, Sagent Agila LLC distributed $3,022 to its joint venture partners.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	Note 25. Quarterly Financial Data (Unaudited) 2015 Quarters First Second Third Fourth Net revenue $ 82,645 $ 77,345 $ 75,199 $ 83,107 Gross profit $ 21,925 $ 18,441 $ 24,362 $ 23,011 Income (loss) from continuing operations $ (189 ) $ 1,191 $ 1,742 $ (47,265 ) Net loss $ 1,894 $ 256 $ 1,795 $ 17,937 Weighted-average shares used to compute net income per share Basic 32,043 32,161 32,747 32,793 Diluted 32,043 32,161 32,747 32,793 Net income per share Basic $ (0.06 ) $ (0.01 ) $ (0.05 ) $ (0.55 ) Diluted $ (0.06 ) $ (0.01 ) $ (0.05 ) $ (0.55 ) 2014 Quarters First Second Third Fourth (Restated) Net revenue $ 70,869 $ 69,194 $ 65,359 $ 83,561 Gross profit $ 20,384 $ 22,592 $ 18,770 $ 24,416 Income from continuing operations $ 6,632 $ 3,318 $ 4,044 $ 5,050 Net income $ 5,119 $ 3,069 $ 1,926 $ 26,837 Weighted-average shares used to compute net loss per share Basic 31,814 31,873 31,895 31,945 Diluted 32,614 32,665 32,960 33,031 Net income per share Basic $ 0.16 $ 0.10 $ 0.06 $ 0.84 Diluted $ 0.16 $ 0.09 $ 0.06 $ 0.81 In connection with the restatement as described in Note 2. Restatement, on Net Income, Net income per share (basic) and Net income per share (diluted) were adjusted by $2,930, $0.09 and $0.09, respectively.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	Sagent Pharmaceuticals, Inc. Valuation and Qualifying Accounts For the years ended December 31, 2015, 2014 and 2013 (in thousands) Col. A Col. B Col. C Col. D Col. E Description Balance at Beginning of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End of Period Chargeback Allowance Year ended December 31, 2015 $ 63,088 $ 318,605 $ — $ 333,105 $ 48,588 Year ended December 31, 2014 $ 43,682 $ 403,493 $ — $ 384,087 $ 63,088 Year ended December 31, 2013 $ 24,265 $ 300,835 $ — $ 281,418 $ 43,682 Allowance for Cash Discounts Year ended December 31, 2015 $ 2,440 $ 15,655 $ — $ 14,178 $ 3,917 Year ended December 31, 2014 $ 2,414 $ 13,364 $ — $ 13,338 $ 2,440 Year ended December 31, 2013 $ 1,373 $ 12,204 $ — $ 11,163 $ 2,414 Allowance for Credits Year ended December 31, 2015 $ 15,860 $ 6,626 $ — $ 15,444 $ 7,042 Year ended December 31, 2014 $ 4,895 $ 23,406 $ — $ 12,441 $ 15,860 Year ended December 31, 2013 $ 3,262 $ 6,760 $ — $ 5,127 $ 4,895 Deferred Tax Valuation Allowance Year ended December 31, 2015 $ 9,950 $ 15,094 $ — $ 544 $ 24,500 Year ended December 31, 2014 (restated) $ 42,109 $ 11,164 $ — $ 43,323 $ 9,950 Year ended December 31, 2013 $ 46,657 $ 1,158 $ 5,843 $ 11,549 $ 42,109 Inventory Reserve Allowance Year ended December 31, 2015 $ 3,242 $ 2,097 $ — $ 339 $ 5,000 Year ended December 31, 2014 $ 5,099 $ 2,238 $ 508 $ 4,603 $ 3,242 Year ended December 31, 2013 $ 2,021 $ 3,078 $ — $ — $ 5,099 Allowance for Doubtful Accounts Year ended December 31, 2015 $ 1,433 $ 312 $ — $ 1,702 $ 43 Year ended December 31, 2014 $ 23 $ 1,440 $ — $ 30 $ 1,433 Year ended December 31, 2013 $ 124 $ — $ — $ 101 $ 23

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Sagent Pharmaceuticals, Inc. (“Sagent”, “we”, “us” or “our”) is a leading provider of affordable pharmaceuticals to the hospital market, which we sell primarily throughout North America. We completed our initial public offering (“IPO”) on April 26, 2011. In connection with our IPO, we incorporated (the “Reincorporation”) in Delaware as Sagent Pharmaceuticals, Inc. Prior to the Reincorporation, we were a Cayman Islands company, and our corporate name was Sagent Holding Co. (“Sagent Holding”). Our products are typically sold to pharmaceutical wholesale companies which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The injectable pharmaceutical marketplace is comprised of end users who have relationships with group purchasing organizations (GPOs) or specialty distributors that focus on a particular therapeutic class. GPOs enter into product purchasing agreements with Sagent and other pharmaceutical suppliers for products in an effort to secure favorable drug pricing on behalf of their end-user members.
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The consolidated financial statements include the assets, liabilities, and results of operations of Sagent Pharmaceuticals, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Sagent Agila LLC (“Sagent Agila”) is a joint venture incorporated in Wyoming with Strides Inc., a wholly-owned subsidiary of Strides Arcolab International Limited (“Strides”), established in January 2007 with the principal business of development, manufacturing, marketing, distribution and sale of generic pharmaceutical products to the U.S. market. In December 2013, Mylan Inc. (“Mylan”) acquired Strides’ Agila Specialities Pvt. Ltd., subsidiary (“Agila”), including Strides’ ownership share of the Sagent Agila joint venture. We account for our 50% interest in Sagent Agila under the equity method of accounting as our interest in the entity provides for joint financial and operational control. Sagent’s equity in the net income (loss) of Sagent Agila is included in the accompanying consolidated statements of operations as equity in net income (loss) of joint ventures. On June 4, 2013, we acquired the remaining 50% equity interest in Kanghong Sagent (Chengdu) Pharmaceutical Co. Ltd. (“KSCP”) from our former joint venture partner (the “SCP Acquisition”), and accordingly, the consolidated financial statements since that date include KSCP as a wholly-owned subsidiary. Prior to the SCP Acquisition, we accounted for our investment in KSCP using the equity method of accounting, as our interest in the entity provided for joint financial and operational control, and the operating results of KSCP were reported on a one-month lag. In August 2013, we formally changed the name of this entity to Sagent (China) Pharmaceuticals Co., Ltd. (“SCP”). On October 1, 2014, we, through our wholly-owned subsidiary, Sagent Acquisition Corp., a Canadian company, acquired all of the issued and outstanding shares of the capital stock of 7685947 Canada Inc., and its subsidiary, Omega Laboratories Limited (collectively, “Omega”), a privately held Canadian pharmaceutical and specialty healthcare products company for C$92.8 million ($82.7 million). As a result of the completion of the transaction, Omega became a wholly-owned subsidiary of the Company effective October 1, 2014. As a result of the Omega acquisition on October 1, 2014, we began operating in two reportable segments comprised of operations in the United States, including our Chinese manufacturing site, (Sagent US segment) and Canada (Omega segment), each of which develop, source, manufacture and market generic injectable products for sale within the their respective countries, each segment deriving a significant portion of its revenues from a single class of pharmaceutical wholesale customers within that country. On December 29, 2015, our Board of Directors authorized us to proceed with a sale of all of the Company’s ownership interests in SCP. Following this decision, we have classified SCP as held for sale in our Consolidated Balance Sheet as of December 31, 2015.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currencies	Foreign Currencies We translate the results of operations of our foreign subsidiaries using average exchange rates during each period, whereas balance sheet accounts are translated using exchange rates at the end of each period. We record currency translation adjustments as a component of equity. Transaction gains and losses are recorded in interest income and other in the statements of operations, and were $2,838 and $1,075 of transaction losses in the year ended December 31, 2015 and 2014, respectively. Transaction gains and losses were not significant for the year ended December 31, 2013.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the balance sheets for cash and cash equivalents and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents These amounts are stated at cost, which approximates fair value. At December 31, 2015, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances. The majority of our funds at December 31, 2015 were maintained at stable financial institutions, in amounts in excess of federally insured limits. This represents a concentration of credit risk. We have not experienced any losses on our deposits of cash and cash equivalents to date. Cash collateral pledged under various lease agreements and cash restricted by financing agreements is classified as restricted cash within the other assets caption in the accompanying consolidated balance sheets as our ability to withdraw the funds is contractually limited.
Financial Instruments	Financial Instruments We consider all highly liquid money market investments with a maturity of three months or less at the date of purchase to be cash equivalents. The carrying values of these investments approximate their fair values. Investments with original maturities of greater than three months and remaining maturities of less than one year are classified as short-term investments. Investments with maturities beyond one year are classified as short-term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. All cash equivalents and short-term investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income (“OCI”). Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. We employ a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, we evaluate, among other factors, general market conditions, credit quality of debt instrument issuers, the duration and extent to which the fair value is less than cost, and for equity securities, our intent and ability to hold, or plans to sell, the investment. For fixed income securities, we also evaluate whether we have plans to sell the security or it is more likely than not that we will be required to sell the security before recovery. We also consider specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to other expense and a new cost basis in the investment is established.
Inventories	Inventories Inventories are stated at the lower of cost (first in, first out) or market value. Inventories consist of products currently approved for marketing and may include certain products pending regulatory approval. From time to time, we capitalize inventory costs associated with products prior to receiving regulatory approval based on our judgment of probable future commercial success and realizable value. Such judgment incorporates management’s knowledge and best judgment of where the product is in the regulatory review process, market conditions, competing products and economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. If final regulatory approval for such products is denied or delayed, we may need to reserve for and expense such inventory. We record inventory provisions for products which have not received regulatory approval within product development expense. We establish reserves for inventory to reflect situations in which the cost of the inventory is not expected to be recovered. In evaluating whether inventory is stated at the lower of cost or market, management considers such factors as the amount of inventory on hand, estimated time required to sell such inventory, remaining shelf life and current expected market conditions, including level of competition. We record provisions for inventory to cost of goods sold.
Property, Plant, and Equipment	Property, Plant, and Equipment Property, plant, and equipment is stated at cost, less accumulated depreciation. The cost of repairs and maintenance is expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Provisions for depreciation are computed for financial reporting purposes using the straight-line method over the estimated useful life of the related asset and for leasehold improvements over the lesser of the estimated useful life of the related asset or the term of the related lease as follows: Land and land improvements Indefinite, except with respect to the Chinese land use right (through remaining term, June 2057) Building and improvements 5 to 40 years or remaining term of lease Machinery, equipment, furniture, and fixtures 3 to 10 years Software 3 to 5 years Property, plant and equipment that is purchased or constructed which requires a period of time before the assets are ready for their intended use are accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including installation costs and associated interest costs. Construction-in-progress is transferred to specific property, plant and equipment accounts and commences depreciation when these assets are ready for their intended use. The capitalization of interest costs commences when expenditures for the asset have been made, activities that are necessary to prepare the asset for its intended use are in progress and interest cost is being incurred. The capitalization period ends when the asset is substantially complete and ready for its intended use.
Deferred Financing Costs	Deferred Financing Costs Deferred financing costs related to the issuance of debt are amortized using the straight-line method over the term of the related debt instrument, which approximates the effective interest method. We capitalized deferred financing costs of $274 in 2015 in connection with our amended and restated senior secured credit facility with Chase (the “Amended Chase Agreement”) and $285 in 2014 in connection with our new revolving loan credit facility with Chase (the “Chase Agreement”). Deferred financing costs are recorded within Other Assets on our consolidated balance sheets, as there are no outstanding balances related to these loans, and totaled $468 and $275 at December 31, 2015 and 2014, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We evaluate long-lived assets, including intangible assets with definite lives, for impairment whenever events or other changes in circumstances indicate that the carrying value of an asset may no longer be recoverable. An evaluation of recoverability is performed by comparing the carrying values of the assets to projected future undiscounted cash flows, in addition to other quantitative and qualitative analyses. Judgments made by management related to the expected useful lives of long-lived assets and the ability to realize undiscounted cash flows in excess of the carrying amounts of such assets are affected by factors such as changes in economic conditions and changes in operating performance. Upon indication that the carrying values of such assets may not be recoverable, we recognize an impairment loss as a charge against current operations. We recorded an impairment charge within cost of sales of $200 related to one product license right in the year ended December 31, 2014. In December 2015, we recorded an impairment charge within operating expense of $45,158 related to classifying SCP as held for sale.
Product Development Agreements	Product Development Agreements Product development costs are expensed as incurred. These expenses include the costs of our internal product development efforts and acquired in-process research and development, as well as product development costs incurred in connection with our third-party contract research and development efforts. Non-refundable contractual payments made under contract research and development arrangements for future research and development activities prior to regulatory approval, including payments made upon execution of a definitive contract research and development agreement, are deferred and are expensed as the related services are performed. If we determine that it is no longer probable that the product will be pursued, any related capitalized amount is expensed in the current period. Contractual payments due to a counterparty for development efforts that are contingent upon the successful completion of certain activities are expensed when the successful completion is considered probable. Once a product receives regulatory approval, we record any contractual payments for the license to sell the developed product as an intangible asset to be amortized on a straight-line basis as a component of cost of sales over the shorter of the related license period or the estimated life of the acquired product. At December 31, 2015, the amortization period for intangible assets arising from approved products ranges from four to six years with a weighted-average period prior to the next renewal or extension of 4.3 years. We make the determination whether to capitalize or expense amounts related to the development of new products and technologies through agreements with third parties based on our ability to recover our cost in a reasonable period of time, generally the initial license term, from the estimated future cash flows anticipated to be generated pursuant to each agreement. Market, regulatory and legal factors, among other things, may affect the realizability of the projected cash flows that an agreement was initially expected to generate. We regularly monitor these factors and subject capitalized costs to periodic impairment testing.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill is recognized as the excess of fair value of consideration transferred to acquire an entity over the fair values assigned to assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for impairment on an annual basis and more often if circumstances require. We assess goodwill impairment risk by first performing a qualitative review of entity-specific, industry, market and general economic factors for each of our reporting units. If significant potential goodwill impairment risk exists, we apply a two-step quantitative test. Impairment losses are recognized whenever the implied fair value of goodwill is less than its carrying value. We test goodwill for impairment at least annually on October 1. Certain amounts paid to third parties related to the development of new products and technologies are capitalized and included within intangible assets. We determine the estimated fair values of certain intangible assets with definitive lives utilizing valuations performed by management at the time of their acquisition, based on anticipated future cash flow activity. We test indefinite-lived intangible assets for impairment by first performing a qualitative review by assessing events and circumstances that could affect the fair value or carrying value of the indefinite-lived intangible asset. If significant potential impairment risk exists for a specific indefinite-lived intangible asset, we quantitatively test for impairment by comparing the fair value of each intangible asset with its carrying value. Fair value of non-amortizable intangible assets is determined using planned growth rates, market-based discount rates and estimates of royalty rates. If the carrying value of the asset exceeds its fair value, the intangible asset is considered impaired and is reduced to its estimated fair value. Definite-lived intangible assets are amortized over their estimated useful lives and evaluated for impairment on a quarterly basis as long-lived assets.
Acquired In-Process Research and Development	Acquired In-Process Research and Development The fair value of in-process research and development (“IPR&D”) projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off to product development expense. Development costs incurred after the acquisition are expensed as incurred.
Advertising and Promotion Expense	Advertising and Promotion Expense All advertising and promotion costs are expensed as selling, general, and administrative expenses when incurred. Total direct advertising and promotion expense incurred was $1,173, $1,112, and $766 for the years ended December 31, 2015, 2014 and 2013, respectively.
Income Taxes	Income Taxes Provisions for federal, state and foreign taxes are calculated based on pre-tax earnings at currently enacted tax rates. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss and capital loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the financial statements in the period that includes the legislative enactment date. We recognize the financial statement effects of a tax position only when it is more likely than not that the position will be sustained upon examination and recognize any interest and penalties accrued in relation to unrecognized tax benefits in income tax expense. We establish valuation allowances against deferred tax assets when it is more likely than not that the realization of those deferred tax assets will not occur. In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We also consider the scheduled reversal of deferred tax liabilities, projected future taxable income or losses, and tax planning strategies in making this assessment.
Revenue Recognition - General	Revenue Recognition – General We recognize revenue when our obligations to a customer are fulfilled relative to a specific product and all of the following conditions are satisfied: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) delivery has occurred. Delivery is deemed to have occurred upon customer receipt of product, upon fulfillment of acceptance terms, if any, and when no significant contractual obligations remain. Net sales reflect reductions of gross sales for estimated wholesaler chargebacks, estimated contractual allowances, estimated product returns and estimated early payment discounts. We provide for estimated product returns at the time of sale based on historic product return experience. In the case of new products for which the product introduction is not an extension of an existing line of product, where we determine that there are not products in a similar therapeutic category, or where we determine the new product has dissimilar characteristics with existing products, such that we cannot reliably estimate expected returns of the new product, we defer recognition of revenue until the right of return no longer exists or until we have developed sufficient historical experience to estimate sales returns. Shipping and handling fees billed to customers are recognized in net revenue. Other shipping and handling costs are included in cost of goods sold.
Revenue Recognition - Chargebacks	Revenue Recognition – Chargebacks The majority of our products are distributed through independent pharmaceutical wholesalers. In accordance with industry practice, sales to wholesalers are initially transacted at wholesale list price. The wholesalers then generally sell to an end user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously contractually established between the end user and Sagent. When we initially record a sale to a wholesaler, the sale and resulting receivable are recorded at our list price. However, experience indicates that most of these selling prices will eventually be reduced to a lower, end-user contract price. Therefore, at the time of the sale, a contra asset is recorded for, and revenue is reduced by, the difference between the list price and the estimated average end-user contract price. This contra asset is calculated by product code, taking the expected number of outstanding wholesale units sold that will ultimately be sold under end-user contracts multiplied by the anticipated, weighted-average contract price. When the wholesaler ultimately sells the product, the wholesaler charges us, or issues a chargeback, for the difference between the list price and the end-user contract price and such chargeback is offset against the initial estimated contra asset. Periodically, we review the wholesale list prices for our products, and from time to time may reduce list prices based on market conditions or competitive pricing pressures. Reductions in the wholesale list price of our products reduce both our gross sales and the revenue reduction recorded upon initial product sale, but do not change the end-user contract selling price. The significant estimates inherent in the initial chargeback provision relate to wholesale units pending chargeback and to the ultimate end-user contract-selling price. We base the estimate for these factors on product-specific sales and internal chargeback processing experience, estimated wholesaler inventory stocking levels, current contract pricing and our expectation for future contract pricing changes. Our chargeback provision is potentially impacted by a number of market conditions, including: competitive pricing, competitive products, and other changes impacting demand in both the distribution channel and end users. We rely on internal data, external data from our wholesaler customers, and management estimates to estimate the amount of inventory in the channel subject to future chargeback. The amount of product in the channel is comprised of both product at the wholesaler and product that the wholesaler has sold, but not yet reported as end-user sales. Physical inventory in the channel is estimated by the evaluation of our monthly sales to the wholesalers and our knowledge of inventory levels and estimated inventory turnover at these wholesalers. Our total chargeback accrual was $48,588 and $63,088 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable. Our total chargeback expense was $318,605, $403,493, and $300,835 for the years ended December 31, 2015, 2014 and 2013, respectively.
Revenue Recognition - Cash Discounts	Revenue Recognition – Cash Discounts We offer cash discounts, approximating 2% of the gross sales price, as an incentive for prompt payment and occasionally offer greater discounts and extended payment terms in support of product launches or other promotional programs. Our wholesale customers typically pay within terms, and we account for cash discounts by reducing net sales and accounts receivable by the full amount of the discount offered at the time of sale. We consider payment performance and adjust the accrual to reflect actual experience. Our total accrual for cash discounts was $3,917 and $2,440 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable.
Revenue Recognition - Sales Returns	Revenue Recognition – Sales Returns Consistent with industry practice, our return policy permits customers to return products within a window of time before and after the expiration of product dating. We provide for product returns and other customer credits at the time of sale by applying historical experience factors. We provide specifically for known outstanding returns and credits. The effect of any changes in estimated returns is taken in the current period’s income. We determine our estimate of the sales return accrual primarily based on historical experience, but also consider other factors that could impact sales returns. These factors include levels of inventory in the distribution channel, estimated shelf life, product recalls, timing of product returns relative to expiry, product discontinuances, price changes of competitive products, and introductions of competitive new products. Our total accrual for returns and credits was $7,042 and $15,860 at December 31, 2015 and 2014, respectively, and is included as a reduction of accounts receivable.
Revenue Recognition - Contractual Allowances	Revenue Recognition – Contractual Allowances Contractual allowances, generally rebates or administrative fees, are offered to certain wholesale customers, GPOs, and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to five months from date of sale. We provide a provision for contractual allowances at the time of sale based on the historical relationship between sales and such allowances. Contractual allowances are reflected in the consolidated financial statements as a reduction of revenues and as a current accrued liability.
Stock Based Compensation	Stock Based Compensation We recognize compensation cost for all share-based payments (including employee stock options) at fair value. We use the straight-line attribution method to recognize stock based compensation expense over the vesting period of the award. Options currently granted generally expire ten years from the grant date and vest ratably over a four-year period. Stock based compensation expense for performance based options is measured and recognized if the performance measures are considered probable of being achieved. We evaluate the probability of the achievement of the performance measures at each balance sheet date. If it is not probable that the performance measures will be achieved, any previously recognized compensation cost would be reversed. We use the Black-Scholes option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under the stock participation plan. Stock-based compensation expense was $3,836, $2,683 and $5,293 for the years ended December 31, 2015, 2014 and 2013, respectively.
Recently Adopted and Pending Accounting Standards	Recently Adopted and Pending Accounting Standards In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB approved a one year deferral to the new revenue guidance, and we are therefore required to adopt the new guidance on January 1, 2018 using one of the two prescribed retroactive methods. We are evaluating the impact of the amended revenue recognition guidance on our consolidated financial statements. In February 2015, the FASB issued amended guidance on the model used to evaluate whether certain legal entities should be consolidated. This guidance is effective for the Company in the first quarter of 2017. Early adoption is permitted. Adoption of this guidance is not expected to have a material impact on our financial statements. In April 2015, the FASB issued amended guidance, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim periods beginning after December 15, 2015. Adoption of this guidance in the first quarter 2016, is not expected to have a material impact on our financial statements. In September 2015, the FASB issued guidance that eliminates the requirement to restate prior period financial statements for measurement period adjustments related to business combinations. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. In addition, separate presentation on the face of the income statement or disclosure in the notes to the financial statements is required regarding the portion of the adjustment recorded in current period earnings. We are required to adopt this guidance prospectively for measurement period adjustments that occur after the effective date. This guidance is effective for the Company in the first quarter of 2016. Early adoption is permitted. We have adopted this guidance in the current period. There was no material impact of adoption. In November 2015, the FASB issued guidance that requires all deferred tax assets and liabilities to be presented as non-current in a classified statement of financial position. We are required to adopt this guidance by the first quarter of 2017, with early adoption permitted. We have adopted this guidance in our Consolidated Balance Sheet as of December 31, 2015 and retrospectively for December 31, 2014. Adoption of this standard resulted in the reclassification of $12,135 of current deferred tax assets to long term deferred tax assets at December 31, 2014. In February 2016, the FASB issued lease guidance, which is intended to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. In order to meet that objective, the new standard requires recognition of the assets and liabilities that arise from leases. A lessee will be required to recognize on the balance sheet the assets and liabilities for leases with lease terms of more than 12 months. Accounting by lessors will remain largely unchanged from current U.S. generally accepted accounting principles. The new standard is effective for public companies for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. The Company is currently evaluating the effect that adopting this standard will have on our financial statements and related disclosures.

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Estimated Useful Life of Assets and Leasehold Improvements	Provisions for depreciation are computed for financial reporting purposes using the straight-line method over the estimated useful life of the related asset and for leasehold improvements over the lesser of the estimated useful life of the related asset or the term of the related lease as follows: Land and land improvements Indefinite, except with respect to the Chinese land use right (through remaining term, June 2057) Building and improvements 5 to 40 years or remaining term of lease Machinery, equipment, furniture, and fixtures 3 to 10 years Software 3 to 5 years

Restatement (Tables)

Restatement (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Effects of These Prior Period Errors Consolidated Financial Statements	The effects of these prior period errors on the consolidated financial statements after the retrospective adoption of deferred tax asset and liability presentation guidance as described in Note 1, are as follows: Consolidated Statements of Operations (in thousands, except per share amounts) Year ended December 31, 2014 As reported Adjustments As restated Net revenue $ 288,983 $ — $ 288,983 Cost of sales 202,821 — 202,821 Gross profit 86,162 — 86,162 Operating expenses: Product development 26,809 — 26,809 Selling, general and administrative 43,227 — 43,227 Acquisition-related costs 1,069 — 1,069 Equity in net income of joint ventures (3,987 ) — (3,987 ) Total operating expenses 67,118 — 67,118 Income (loss) from operations 19,044 — 19,044 Interest income and other income (expense) (678 ) — (678 ) Interest expense (2,188 ) — (2,188 ) Income (loss) before income taxes 16,178 — 16,178 Provision (benefit) for income taxes (23,703 ) 2,930 (20,773 ) Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Net income (loss) per common share: Basic $ 1.25 $ (0.09 ) $ 1.16 Diluted $ 1.22 $ (0.09 ) $ 1.13 Weighted-average of shares used to compute net income (loss) per common share: Basic 31,882 — 31,882 Diluted 32,745 — 32,745 Consolidated Statements of Comprehensive Income (Loss) (in thousands) Year ended December 31, 2014 As reported Adjustments As restated Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Other comprehensive income (loss), net of tax Foreign currency translation adjustments (3,830 ) — (3,830 ) Unrealized gains (losses) gains on available for sale securities (31 ) — (31 ) Total other comprehensive income (loss), net of tax (3,861 ) — (3,861 ) Comprehensive income (loss) $ 36,020 $ (2,930 ) $ 33,090 Consolidated Balance Sheet (in thousands, except per share amounts) As of December 31, 2014 As reported Adjustments As restated Assets Current assets: Cash and cash equivalents $ 55,633 $ — $ 55,633 Short-term investments 18,473 — 18,473 Accounts receivable, net of chargebacks and other deductions 42,780 — 42,780 Inventories, net 61,781 — 61,781 Due from related party 2,156 — 2,156 Prepaid expenses and other current assets 5,560 — 5,560 186,383 — 186,383 Property, plant, and equipment, net 71,153 — 71,153 Investment in joint ventures 4,539 — 4,539 Goodwill 28,155 — 28,155 Intangible assets, net 65,575 — 65,575 Non-current deferred tax assets 25,308 (1,530 ) 23,778 Other assets 375 — 375 Total assets $ 381,488 $ (1,530 ) $ 379,958 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 32,710 $ — $ 32,710 Due to related party 8,079 — 8,079 Accrued profit sharing 10,684 — 10,684 Accrued liabilities 19,346 — 19,346 Current portion of deferred purchase consideration 8,725 — 8,725 Current portion of long-term debt 508 — 508 Notes payable 5,499 — 5,499 Total current liabilities 85,551 — 85,551 Long term liabilities: Long-term debt 1,945 — 1,945 Deferred income taxes 15,706 — 15,706 Other long-term liabilities 2,534 420 2,954 Total liabilities 105,736 420 106,156 Stockholders’ equity: Common stock – $0.01 par value, 100,000,000 authorized, and 32,801,896 and 31,976,661 outstanding at December 31, 2015 and December 31, 2014, respectively 320 — 320 Additional paid-in capital 352,982 980 353,962 Accumulated other comprehensive income (loss) (3,374 ) — (3,374 ) Accumulated deficit (74,176 ) (2,930 ) (77,106 ) Total stockholders’ equity 275,752 (1,950 ) 273,802 Total liabilities and stockholders’ equity $ 381,488 $ (1,530 ) $ 379,958 Consolidated Statements of Cash Flows (in thousands) Year ended December 31, As reported Adjustments As restated Cash flows from operating activities Net income (loss) $ 39,881 $ (2,930 ) $ 36,951 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 9,524 — 9,524 Stock-based compensation 2,683 — 2,683 Equity in net income of joint ventures (3,987 ) — (3,987 ) Dividends from unconsolidated joint ventures 1,511 — 1,511 Gain on previously held equity interest — — — Deferred income taxes, net (26,242 ) 2,510 (23,732 ) Other (200 ) (980 ) (1,180 ) Changes in operating assets and liabilities, net of effect of acquisition: Accounts receivable (16,442 ) — (16,442 ) Inventories, net (1,713 ) — (1,713 ) Prepaid expenses and other current assets 2,171 — 2,171 Due from related party (1,208 ) — (1,208 ) Accounts payable and other accrued liabilities 17,201 420 17,621 Net cash provided by (used in) operating activities 23,179 (980 ) 22,199 Cash flows from investing activities Capital expenditures (4,242 ) — (4,242 ) Acquisition of business, net of cash acquired (86,467 ) — (86,467 ) Purchases of investments (87,171 ) — (87,171 ) Sale of investments 181,352 — 181,352 Purchase of product rights (4,404 ) — (4,404 ) Other — — — Net cash (used in) provided by investing activities (932 ) — (932 ) Cash flows from financing activities Increase (reduction) in short-term borrowings 1,152 — 1,152 Repayment of long-term debt (10,420 ) — (10,420 ) Proceeds from issuance of common stock, net of issuance costs 1,023 — 1,023 Payment of deferred financing costs (285 ) — (285 ) Excess tax benefits on stock option exercises — 980 980 Net cash (used in) provided by financing activities (8,530 ) 980 (7,550 ) Effect of exchange rate movements in cash (416 ) — (416 ) Net increase (decrease) in cash and cash equivalents 13,301 — 13,301 Cash and cash equivalents, at beginning of period 42,332 — 42,332 Cash and cash equivalents, at end of period $ 55,633 $ — $ 55,633 Supplemental disclosure of cash flow information Acquisition of property, plant and equipment in accounts payable $ 934 $ — $ 934 Cash paid for interest $ 1,361 $ — $ 1,361 Cash paid for taxes $ 2,555 $ — $ 2,555

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Condensed Balance Sheet Information	Condensed balance sheet information of SCP as of December 31, 2015 is presented below. December 31, Condensed balance sheet information Accounts receivable, net 8 Inventories, net 3,529 Property, plant, and equipment, net 500 Other assets 589 Total assets of SCP as held for sale in the Balance Sheet $ 4,626 Accounts payable $ 722 Accrued liabilities 1,876 Other liabilities 312 Total liabilities of SCP as held for sale in the Balance Sheet $ 2,910

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Omega
Fair value of transferred	The acquisition date fair value transferred for the purchase of Omega is as follows: (in thousands) Cash $ 82,863 Net working capital adjustments receivable from the sellers (170 ) Total purchase consideration $ 82,693
Fair Value of Identifiable Assets Acquired and Liabilities Assumed	The fair value of identifiable assets acquired and liabilities assumed for the Omega acquisition is shown in the table below: (in thousands) Cash $ 3 Accounts receivable, net 3,419 Inventory 14,014 Prepaid and other current assets 1,295 Property, plant and equipment 14,307 Definite-lived intangible assets 49,918 In-process research and development 7,666 Goodwill 22,842 Accounts payable (2,410 ) Other accrued liabilities (4,090 ) Long-term debt and notes payable (7,095 ) Deferred income tax liabilities (17,176 ) Total allocation of fair value $ 82,693
Unaudited Pro Forma Financial Information	The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if the Omega acquisition had taken place on January 1, 2014. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date. Year Ended 2014 (As Restated) Condensed statement of operations information Net revenues $ 312,853 Net income 35,462 Diluted income per common share $ 1.08
SCP
Fair value of transferred	The acquisition date fair value transferred for the purchase of SCP is as follows: (in thousands) Cash $ 10,000 Present value of remaining purchase consideration 13,836 Previously held equity interest 15,949 Gain on remeasurement of previously held equity interest in KSCP 154 Total purchase consideration $ 39,939
Fair Value of Identifiable Assets Acquired and Liabilities Assumed	The fair value of identifiable assets acquired and liabilities assumed for the SCP Acquisition is shown in the table below: (in thousands) Goodwill $ 6,038 Acquired tangible assets, net of assumed liabilities 33,901 Total allocation of fair value $ 39,939
Unaudited Pro Forma Financial Information	The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if the SCP acquisition had taken place on January 1, 2013. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date. Year Ended December 31, 2013 Condensed statement of operations information Net revenues $ 244,750 Net income 25,881 Diluted income per common share $ 0.86
Mustafa NevzatIlac Sanayii A S
Fair Value of Identifiable Assets Acquired and Liabilities Assumed	The estimated fair value of identifiable assets acquired for these product rights is shown in the table below: (in thousands) Definite-lived intangible assets $ 3,000 Total allocation of fair value $ 3,000
Sagent Agila LLC
Fair Value of Identifiable Assets Acquired and Liabilities Assumed	The estimated fair value of identifiable assets acquired and liabilities assumed for Rocuronium, Clindamycin, and Cisatracurium is shown in the table below: (in thousands) Definite-lived intangible assets $ 720 In-process research and development 1,040 Total allocation of fair value $ 1,760 The fair value of identifiable assets acquired and liabilities assumed for Mesna and Acetylcysteine is shown in the table below: (in thousands) Definite-lived intangible asset $ 2,180 In-process research and development 1,220 Total allocation of fair value $ 3,400

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments	Our investments at December 31, 2015 were comprised of the following: Cost basis Unrealized gains Unrealized Carrying value Cash and equivalents Short term investments Assets Cash $ 15,124 $ — $ — $ 15,124 $ 15,124 $ — Money market funds 13,838 — — 13,838 13,838 — Corporate bonds and notes 20,128 — (68 ) 20,060 — 20,060 $ 49,090 $ — $ (68 ) $ 49,022 $ 28,962 $ 20,060 Our investments at December 31, 2014 were comprised of the following: Cost basis Unrealized Unrealized Carrying Cash and Short term Assets Cash $ 42,494 $ — $ — $ 42,494 $ 42,494 $ — Money market funds 13,139 — — 13,139 13,139 — Corporate bonds and notes 18,513 1 (41 ) 18,473 — 18,473 $ 74,146 $ 1 $ (41 ) $ 74,106 $ 55,633 $ 18,473
Investments with Continuous Unrealized Losses for Less Than Twelve Months and Related Fair Values	Investments with continuous unrealized losses for less than twelve months and their related fair values were as follows: December 31, 2015 December 31, 2014 Fair value Unrealized Fair value Unrealized Corporate bonds and notes 20,060 (68 ) 16,468 (41 )
Cost and Estimated Current Fair Value of Fixed-Income Securities	The original cost and estimated current fair value of our fixed-income securities as of December 31, 2015 are set forth below. Cost basis Estimated fair Due in one year or less $ 9,417 $ 9,406 Between one and five years 10,710 10,654

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Valuation	Inventories at December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Approved Pending Inventory Approved Pending Inventory Raw materials $ 4,855 2,800 7,655 $ 10,203 $ 2,848 $ 13,051 Work in process 433 — 433 2,012 — 2,012 Finished goods 73,365 — 73,365 49,960 — 49,960 Inventory reserve (5,000 ) — (5,000 ) (3,242 ) — (3,242 ) $ 73,653 2,800 76,453 $ 58,933 $ 2,848 $ 61,781

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment at December 31, 2015 and 2014 were as follows: December 31, 2015 2014 Land and land improvements $ 1,102 $ 3,519 Buildings and improvements 6,713 26,605 Machinery, equipment, furniture and fixtures, and software 9,233 42,124 Construction in process 6,535 6,175 23,583 78,423 Less: accumulated depreciation (3,822 ) (7,270 ) $ 19,761 $ 71,153

Investment in Sagent Agila (Tab

Investment in Sagent Agila (Tables) - Sagent Agila LLC	12 Months Ended
	Dec. 31, 2015
Changes in Investment	Changes in the carrying value of Sagent Agila consist of the following: December 31, 2015 2014 Investment in Sagent Agila at beginning of year $ 4,539 $ 2,063 Equity in net income of Sagent Agila 2,569 3,987 Dividend paid — (1,511 ) Investment in Sagent Agila at end of year $ 7,108 $ 4,539
Condensed Statement of Operations Information	Condensed statement of operations and balance sheet information of Sagent Agila is presented below. All amounts are presented in accordance with accounting principles generally accepted in the United States. Year Ended December 31, 2015 2014 2013 Condensed statement of operations information Net revenues $ 9,063 $ 8,093 $ 16,927 Gross profit 5,140 6,321 5,454 Net income 5,138 7,975 8,440
Condensed Statement of Balance Sheet	December 31, 2015 2014 Condensed balance sheet information Current assets $ 17,036 $ 11,333 Noncurrent assets 303 360 Total assets $ 17,339 $ 11,693 Current liabilities $ 3,144 $ 2,636 Long-term liabilities — — Stockholders’ equity 14,195 9,057 Total liabilities and stockholders’ equity $ 17,339 $ 11,693

Goodwill and Intangible asset43

Goodwill and Intangible assets, net (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill by Reportable Segment	Goodwill by reportable segment at December 31, 2015 and 2014 was as follows: 2015 2014 Sagent US $ 6,038 $ 6,038 Omega 19,146 22,117 Goodwill $ 25,184 $ 28,155
Schedule of Intangible Assets - Finite lived	Intangible assets at December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Gross carrying Accumulated Intangible Gross carrying Accumulated Intangible Product licensing rights $ 4,533 (2,998 ) 1,535 $ 4,707 $ (2,878 ) $ 1,829 Product development rights 2,890 — 2,890 4,191 — 4,191 Purchased product rights and other 46,238 (5,087 ) 41,151 51,245 (1,375 ) 49,870 Total definite-lived intangible assets 53,661 (8,085 ) 45,576 60,143 (4,253 ) 55,890 In-process research and development (IPR&D) 7,590 — 7,590 9,685 — 9,685 Total intangible assets $ 61,251 $ (8,085 ) $ 53,166 $ 69,828 $ (4,253 ) $ 65,575
Movements in Intangible Assets	Movements in intangible assets were due to the following: 2015 Product Product Purchased IPR&D Balance at January 1 $ 1,829 $ 4,191 $ 49,870 $ 9,685 Acquisition of product rights 100 1,607 3,000 (864 ) Amortization (394 ) (2,908 ) (4,183 ) — Foreign currency movements — — (7,536 ) (1,231 ) Balance at December 31 $ 1,535 $ 2,890 $ 41,151 $ 7,590 2014 Product Product Purchased IPR&D Balance at January 1 $ 1,690 $ 3,252 $ 2,164 $ 1,220 Acquisition of product rights 946 2,576 — — Sagent Agila product acquisitions — — 720 1,040 Omega acquisition — — 49,918 7,666 Amortization (807 ) (1,637 ) (1,380 ) — Foreign currency movements — (1,552 ) (241 ) Balance at December 31 $ 1,829 $ 4,191 $ 49,870 $ 9,685
Schedule of Estimate Amortization Expense over Each of the Next Five Years	We currently estimate amortization expense over each of the next five years as follows: Amortization For the year ending December 31, 2016 $ 7,132 2017 4,223 2018 4,192 2019 4,121 2020 3,971

Accrued liabilities (Tables)

Accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities at December 31, 2015 and 2014 were as follows: December 31, 2015 2014 Payroll and employee benefits $ 6,512 $ 9,329 Sales and marketing 7,308 6,964 Taxes payable 131 1,040 Other accrued liabilities 1,755 2,013 $ 15,706 $ 19,346

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Summary of Debt Maturities	Debt maturities by year are as follows: December 31, Amount 2016 $ — 2017 — 2018 — 2019 1,623 2020 — 2021 and thereafter — Total long-term debt 1,623 Less: Current maturities of long-term debt — Long-term portion of long-debt $ 1,623

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 consisted of the following: Total fair value Quoted prices in Significant other Significant Assets Money market funds $ 13,838 $ 13,838 — — Corporate bonds and notes 20,060 — $ 20,060 — Commercial paper — — — — Short-term investments $ 33,898 $ 13,838 $ 20,060 — Total assets $ 33,898 $ 13,838 $ 20,060 — Liabilities Contingent purchase consideration $ 50 — — $ 50 The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity. Assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 consisted of the following: Total fair value Quoted prices in Significant other Significant Assets Money market funds $ 13,139 $ 13,139 $ — $ — Corporate bonds and notes 18,513 — 18,513 — Commercial paper — — — — Short-term investments $ 18,513 $ — $ 18,513 $ — Total assets $ 31,652 $ 13,139 $ 18,513 $ — Liabilities Contingent purchase consideration $ 605 $ — $ — $ 605
Summary of Contingent Purchase Consideration Measured Using Significant Unobservable Inputs (Level 3)	During the year ended December 31, 2015, changes in the fair value of our contingent purchase consideration measured using significant unobservable inputs (Level 3), were comprised of the following: Year ended Balance at beginning of period $ 605 Issuance of contingent purchase consideration — Change in fair value of contingent purchase consideration (555 ) Payment of contingent purchase consideration — Balance at end of period $ 50

Accumulated Comprehensive Inc47

Accumulated Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated comprehensive income (loss) at December 31, 2015, 2014 and 2013 is comprised of the following: December 31, 2015 2014 2013 Currency translation adjustment, net of tax $ (17,414 ) $ (3,334 ) $ 496 Unrealized gain (loss) on available for sale securities, net of tax (68 ) (40 ) (9 ) $ (17,482 ) $ (3,374 ) $ 487 The following table summarizes the changes in balances of each component of accumulated other comprehensive income, net of tax as of December 31, 2015. Currency Unrealized gains Total Balance as of December 31, 2014 $ (3,334 ) $ (40 ) $ (3,374 ) Other comprehensive income (loss) before reclassifications (14,080 ) (28 ) (14,108 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive loss (14,080 ) (28 ) (14,108 ) Balance as of December 31, 2015 $ (17,414 ) (68 ) (17,482 ) Currency Unrealized gains Total Balance as of December 31, 2013 $ 496 $ (9 ) $ 487 Other comprehensive income (loss) before reclassifications (3,830 ) (31 ) (3,861 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive loss (3,830 ) (31 ) (3,861 ) Balance as of December 31, 2014 $ (3,334 ) $ (40 ) $ (3,374 ) Currency Unrealized gains Total Balance as of December 31, 2012 $ 2,488 $ 12 $ 2,500 Other comprehensive income (loss) before reclassifications 790 (21 ) 769 Amounts reclassified from accumulated other comprehensive income (loss) (2,782 ) — (2,782 ) Net current-period other comprehensive loss (1,992 ) (21 ) (2,013 ) Balance as of December 31, 2013 $ 496 $ (9 ) $ 487 No amounts were reclassified out of accumulated other comprehensive income for the years ended December 31, 2015 and 2014. The table below presents the amounts reclassified out of each component of accumulated other comprehensive income for the year ended December 31, 2013. Type of reclassification Amount Affected line item in the condensed consolidated statement of operations Currency translation adjustment – reclassification of cumulative currency translation gain $ 2,782 Gain on previously held equity interest Total reclassification for the year ended December 31, 2013, net of tax $ 2,782

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings Per Share	December 31, 2015, 2014 and 2013, respectively. The table below presents the computation of basic and diluted earnings per share for the years ended December 31, 2015, 2014 and 2013. Year Ended December 31, 2015 2014 (Restated) 2013 Basic and dilutive numerator Net income (loss), as reported $ (21,882 ) $ 36,951 $ 29,594 Denominator Weighted average common shares outstanding – basic (in thousands) 32,439 31,882 29,213 Net effect of dilutive securities Stock options and restricted stock — 863 724 Weighted average common shares outstanding – diluted (in thousands) 32,439 32,745 29,937 Net income (loss) per common share (basic) $ (0.67 ) $ 1.16 $ 1.01

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Restricted Stock Activity	The following table summarizes restricted stock activity during the year ended December 31, 2015: Restricted Weighted-Average Grant Date Fair Value Balance at January 1, 2015 128,209 $ 19.32 Granted 140,971 24.59 Vested (40,496 ) 19.42 Forfeited (48,476 ) 22.10 Balance at December 31, 2015 180,208 $ 22.91
Weighted-Average Assumptions Used in Calculating Estimated Values	The weighted-average estimated values of employee stock option grants and rights granted under the Plans as well as the weighted-average assumptions that were used in calculating such values during the last three years were based on estimates at the date of grant as follows: Risk free interest rate Expected life Expected dividend yield Expected volatility Fair value at grant date 2015 1.74 % 6 years 0 % 52 % $ 10.92 2014 1.92 % 6 years 0 % 61 % $ 11.81 2013 1.24 % 6 years 0 % 62 % $ 9.31
Stock Options Outstanding Vested and Expected to Vest	Stock options outstanding that have vested and are expected to vest as of December 31, 2015, were as follows: Number of shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value (1) Vested 1,021,292 $ 12.96 5.3 4,503 Expected to vest 600,054 $ 22.27 8.5 18 Total 1,621,346 $ 16.61 6.5 4,521 (1) The Aggregate Intrinsic Value amounts represent the difference between the exercise price and $15.91, the fair value of our stock on December 31, 2015, for in-the-money options.
Stock Option Activity	The following table sets forth stock option activity for the year ended December 31, 2015: Options Outstanding Exercisable Options Number of shares Weighted-Average Exercise Price Number of shares Weighted-Average Exercise Price Outstanding at January 1, 2015 2,543,362 14.71 1,622,212 12.04 Granted 411,743 25.11 Exercised (794,528 ) 12.32 Forfeited (481,538 ) 20.93 Outstanding at December 31, 2015 1,679,039 16.61 1,021,292 12.96

Net Revenue by Product (Tables)

Net Revenue by Product (Tables)	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Schedule of Net Revenue by Product Category	Net revenue by product category is as follows: 2015 2014 2013 Therapeutic Class Anti-Infective $ 128,517 $ 102,078 $ 90,604 Critical Care 120,157 87,143 65,612 Oncology 69,622 99,762 88,534 Total $ 318,296 $ 288,983 $ 244,750

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Geographic and Segment Data	Geographic and segment data is as follows: 2015 2014 2013 Net revenue: United States $ 286,773 $ 280,339 $ 244,272 Others 839 83 478 Sagent US segment 287,612 280,422 244,750 Canada (Omega segment) 30,684 8,561 — Total net revenue $ 318,296 288,983 244,750 2015 2014 2013 Long-lived assets: United States $ 80,947 $ 37,252 $ 17,401 China — 52,635 57,016 Sagent US segment 80,947 91,417 74,417 Canada (Omega segment) 77,193 91,553 — Total long-lived assets $ 158,140 $ 181,440 $ 74,417 2015 2014 2013 Depreciation and amortization expense: Sagent US 8,826 8,188 7,074 Omega 4,855 1,336 — Total depreciation and amortization expense $ 13,681 $ 9,524 $ 7,074 2015 2014 2013 Equity in net income of joint ventures: Sagent US $ 2,569 $ 3,987 $ 2,395 Omega — — — Total equity in net income of joint ventures $ 2,569 $ 3,987 $ 2,395 2015 2014 2013 Operating income (loss): Sagent US $ (43,769 ) $ 21,700 $ 31,380 Omega (752 ) (2,656 ) — Total operating income (loss) $ (44,521 ) $ 19,044 $ 31,380 2015 2014 2013 Interest expense: Sagent US $ 564 $ 1,979 $ 930 Omega 206 209 — Total interest expense $ 770 $ 2,188 $ 930 2015 2014 2013 Interest income and other: Sagent US $ (2,495 ) $ 375 $ 205 Omega (295 ) — — Total interest income $ (2,790 ) $ 375 $ 205 2015 2014 (Restated) 2013 Income tax provision (benefit): Sagent US $ (25,993 ) $ (20,034 ) $ 895 Omega (206 ) (739 ) — Total income tax provision (benefit) $ (26,199 ) $ (20,773 ) $ 895 2015 2014 2013 Capital expenditures: Sagent US $ (1,447 ) $ (3,510 ) $ (1,103 ) Omega (5,264 ) (732 ) — Total capital expenditures $ (6,711 ) $ (4,242 ) $ (1,103 ) 2015 2014 (Restated) 2013 Deferred tax assets: Sagent US $ 50,808 $ 23,778 $ 6 Omega — — — Total deferred tax assets $ 50,808 $ 23,778 $ 6 2015 2014 2013 Investment in joint ventures: Sagent US $ 7,108 $ 4,539 $ 2,063 Omega — — — Total investment in joint ventures $ 7,108 $ 4,539 $ 2,063 2015 2014 (Restated) 2013 Total assets: Sagent US $ 258,275 $ 272,283 $ 310,208 Omega 91,457 107,675 — Total assets $ 349,732 $ 379,958 $ 310,208

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	Components of income (loss) before income taxes are as follows: Year Ended December 31, 2015 2014 (Restated) 2013 Domestic $ 8,931 $ 30,200 $ 36,671 Foreign (57,012 ) (14,022 ) (6,182 ) Income (loss) before income taxes $ (48,081 ) $ 16,178 $ 30,489 Provision (benefit) for income taxes: United States federal: Current $ 20 $ 943 $ 895 Deferred (25,887 ) (21,089 ) — (25,867 ) (20,146 ) 895 State and local: Current 937 1,853 — Deferred (1,063 ) (1,740 ) — (126 ) (113 ) — Total United States (25,993 ) (22,964 ) 895 Outside United States: Current 898 205 — Deferred (1,104 ) (944 ) — Total outside United States (206 ) (739 ) — Total provision (benefit) for income taxes $ (26,199 ) $ (20,773 ) $ 895
Net Operating Loss Carryforwards	A summary of our remaining domestic net operating loss carryforwards, including the timing of expiry, is as follows: Year of Expiry Net Operating Loss Carryforwards 2032 300 2034 410 2036 80,325 Total $ 81,035
Reconciliation of Income Tax Provision (Benefit)	The following is a reconciliation of our income tax provision (benefit) computed at the U.S. federal statutory rate to the income tax provision (benefit) reported in the consolidated statements of operations: Year Ended December 31, 2015 2014 (Restated) 2013 Provision (benefit) at statutory rate $ (16,828 ) $ 5,662 $ 10,366 State income taxes, net of federal income tax (373 ) 1,750 230 Foreign rate differential 5,731 1,392 560 Valuation allowance 14,126 (28,672 ) (9,998 ) Worthless stock and bad debt deductions (30,041 ) — — Uncertain tax positions 101 541 — Permanent book / tax differences 164 172 (263 ) Change in tax rate 89 (1,498 ) — Other 832 (120 ) — Provision (benefit) for income taxes $ (26,199 ) $ (20,773 ) $ 895
Deferred Income Tax Assets and Liabilities	The tax effects of temporary differences giving rise to deferred income tax assets and liabilities were: December 31, 2015 2014 (Restated) Deferred tax assets: Product development and start-up costs $ 14,005 $ 12,702 Inventory 3,539 2,493 Loss and credit carryforwards 40,358 9,664 Bad debt reserves 16 549 Accrued expenses / other 4,373 5,244 Deferred compensation 2,979 3,155 Depreciation and amortization 11,482 — Alternative minimum tax carryforwards 1,555 1,546 Total deferred tax assets $ 78,307 $ 35,353 Deferred tax liabilities: Depreciation and amortization $ (3,850 ) $ (2,799 ) Intangible assets (11,070 ) (14,351 ) Inventory (99 ) (180 ) Total deferred tax liabilities (15,019 ) (17,330 ) Net deferred tax asset 63,288 18,023 Valuation allowance (24,501 ) (9,950 ) Net deferred tax assets (liabilities) $ 38,787 $ 8,073
Summary of Unrecognized Tax Benefits	The changes in our unrecognized tax benefits were: Year Ended December 31, 2015 2014 (Restated) 2013 Beginning of year $ 659 $ — $ — Increases from prior year tax positions 136 719 — Decreases relating to settlements with taxing authorities (85 ) (60 ) — Increases from current year positions 16 — — End of year $ 726 $ 659 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingent Payments	Contingent contractual payments are as follows at December 31, 2015: 2016 $ 18,037 2017 4,124 2018 3,726 2019 709 2020 60 2021 and Thereafter 1,065 Total $ 27,721
Future Annual Minimum Lease Payments Related to Non-cancelable Operating Leases	As of December 31, 2015, total future annual minimum lease payments related to non-cancelable operating leases are as follows: 2016 $ 805 2017 501 2018 516 2019 532 2020 404 2021 and Thereafter 134 Total $ 2,892

Quarterly Financial Data (Una54

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	2015 Quarters First Second Third Fourth Net revenue $ 82,645 $ 77,345 $ 75,199 $ 83,107 Gross profit $ 21,925 $ 18,441 $ 24,362 $ 23,011 Income (loss) from continuing operations $ (189 ) $ 1,191 $ 1,742 $ (47,265 ) Net loss $ 1,894 $ 256 $ 1,795 $ 17,937 Weighted-average shares used to compute net income per share Basic 32,043 32,161 32,747 32,793 Diluted 32,043 32,161 32,747 32,793 Net income per share Basic $ (0.06 ) $ (0.01 ) $ (0.05 ) $ (0.55 ) Diluted $ (0.06 ) $ (0.01 ) $ (0.05 ) $ (0.55 ) 2014 Quarters First Second Third Fourth (Restated) Net revenue $ 70,869 $ 69,194 $ 65,359 $ 83,561 Gross profit $ 20,384 $ 22,592 $ 18,770 $ 24,416 Income from continuing operations $ 6,632 $ 3,318 $ 4,044 $ 5,050 Net income $ 5,119 $ 3,069 $ 1,926 $ 26,837 Weighted-average shares used to compute net loss per share Basic 31,814 31,873 31,895 31,945 Diluted 32,614 32,665 32,960 33,031 Net income per share Basic $ 0.16 $ 0.10 $ 0.06 $ 0.84 Diluted $ 0.16 $ 0.09 $ 0.06 $ 0.81

Summary of Significant Accoun55

Summary of Significant Accounting Policies - Additional Information (Detail) CAD in Thousands, $ in Thousands	Oct. 01, 2014USD ($)	Oct. 01, 2014CAD	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Jun. 04, 2013	Dec. 31, 2012USD ($)
Summary Of Significant Accounting Policies [Line Items]
Initial public offering date			Apr. 26, 2011
Percentage of remaining equity interest acquired						50.00%
Foreign currency transaction gain / losses			$ 2,838	$ 1,075
Payment of deferred financing costs			274	285
Impairment charges related to product license			200
Impairment of SCP long-lived assets			$ 45,158
Regulatory approved products, weighted-average amortization period prior to the next renewal or extension			4 years 3 months 18 days
Advertising and promotion expense			$ 1,173	1,112	$ 766
Cash discounts, percentage of gross sales price			2.00%
Stock-based compensation expense			$ 3,836	2,683	5,293
Reclassification of current deferred tax assets to long term deferred tax assets				12,135
Chargeback Allowance
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable, accrual			48,588	63,088	43,682		$ 24,265
Accounts receivable, expense			318,605	403,493	300,835
Allowance for Cash Discounts
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable, accrual			3,917	2,440	2,414		1,373
Accounts receivable, expense			15,655	13,364	12,204
Allowance for Credits
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable, accrual			7,042	15,860	4,895		$ 3,262
Accounts receivable, expense			6,626	23,406	$ 6,760
Other Assets
Summary Of Significant Accounting Policies [Line Items]
Deferred financing costs			$ 468	$ 275
Minimum
Summary Of Significant Accounting Policies [Line Items]
Regulatory approved products, amortization period for intangible assets			4 years
Rebates and fees settlement period			1 month
Maximum
Summary Of Significant Accounting Policies [Line Items]
Regulatory approved products, amortization period for intangible assets			6 years
Rebates and fees settlement period			5 months
Stock Options
Summary Of Significant Accounting Policies [Line Items]
Share based compensation, options granted expiration period			10 years
Share based compensation, options vesting period			4 years
KSCP
Summary Of Significant Accounting Policies [Line Items]
Percentage of remaining equity interest acquired						50.00%
Omega
Summary Of Significant Accounting Policies [Line Items]
Percentage of remaining equity interest acquired	100.00%	100.00%
Business acquisition, purchase price	$ 82,693	CAD 92,768

Estimated Useful Life of Proper

Estimated Useful Life of Property Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2015
Land and land improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	Indefinite, except with respect to the Chinese land use right (through remaining term, June 2057)
Property, plant and equipment, expiration month and year	2057-06
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	5 to 40 years or remaining term of lease
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	5 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	40 years
Machinery, equipment, furniture and fixtures, and software | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	3 years
Machinery, equipment, furniture and fixtures, and software | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	10 years
Software | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	3 years
Software | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life	5 years

Restatement - Additional Inform

Restatement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2013
Error Corrections and Prior Period Adjustments Revision [Line Items]
Valuation allowance									$ 14,126	$ (28,672)	$ (9,998)
Net income (loss)	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Net income (loss) per diluted share	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.81	$ 0.06	$ 0.09	$ 0.16	$ (0.67)	$ 1.13	$ 0.99
Sagent China Pharmaceuticals Co Ltd
Error Corrections and Prior Period Adjustments Revision [Line Items]
Business Combination, step acquisition, equity interest in acquiree, including subsequent acquisition, percentage												100.00%
Business combination, step acquisition, equity interest in acquiree, percentage												50.00%
Unrecorded Adjustment
Error Corrections and Prior Period Adjustments Revision [Line Items]
Net income (loss)										$ (2,930)
Net income (loss) per diluted share										$ (0.09)
Unrecorded Adjustment | Sagent China Pharmaceuticals Co Ltd | Valuation Allowance, Operating Loss Carryforwards
Error Corrections and Prior Period Adjustments Revision [Line Items]
Valuation allowance										$ (2,538)

Restatement of Consolidated Sta

Restatement of Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 83,107	$ 75,199	$ 77,345	$ 82,645	$ 83,561	$ 65,359	$ 69,194	$ 70,869	$ 318,296	$ 288,983	$ 244,750
Cost of sales									230,557	202,821	167,228
Gross profit	23,011	24,362	18,441	21,925	24,416	18,770	22,592	20,384	87,739	86,162	77,522
Operating expenses:
Product development									29,145	26,809	20,275
Selling, general and administrative									49,931	43,227	36,198
Acquisition-related costs									2,838	1,069
Equity in net income of joint ventures									(2,569)	(3,987)	(2,395)
Total operating expenses									84,655	67,118	54,078
Income (loss) from operations	(47,265)	1,742	1,191	(189)	5,050	4,044	3,318	6,632	(44,521)	19,044	31,380
Interest income and other income (expense)									(2,790)	(678)	39
Interest expense									(770)	(2,188)	(930)
Income (loss) before income taxes									(48,081)	16,178	30,489
Provision (benefit) for income taxes									(26,199)	(20,773)	895
Net income (loss)	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Net income (loss) per common share:
Basic	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.84	$ 0.06	$ 0.10	$ 0.16	$ (0.67)	$ 1.16	$ 1.01
Diluted	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.81	$ 0.06	$ 0.09	$ 0.16	$ (0.67)	$ 1.13	$ 0.99
Weighted-average of shares used to compute net income (loss) per common share:
Basic	32,793	32,747	32,161	32,043	31,945	31,895	31,873	31,814	32,439	31,882	29,213
Diluted	32,793	32,747	32,161	32,043	33,031	32,960	32,665	32,614	32,439	32,745	29,937
Scenario, Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue										$ 288,983
Cost of sales										202,821
Gross profit										86,162
Operating expenses:
Product development										26,809
Selling, general and administrative										43,227
Acquisition-related costs										1,069
Equity in net income of joint ventures										(3,987)
Total operating expenses										67,118
Income (loss) from operations										19,044
Interest income and other income (expense)										(678)
Interest expense										(2,188)
Income (loss) before income taxes										16,178
Provision (benefit) for income taxes										(23,703)
Net income (loss)										$ 39,881
Net income (loss) per common share:
Basic										$ 1.25
Diluted										$ 1.22
Weighted-average of shares used to compute net income (loss) per common share:
Basic										31,882
Diluted										32,745
Unrecorded Adjustment
Operating expenses:
Provision (benefit) for income taxes										$ 2,930
Net income (loss)										$ (2,930)
Net income (loss) per common share:
Basic										$ (0.09)
Diluted										$ (0.09)

Restatement of Consolidated S59

Restatement of Consolidated Statements of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Other comprehensive income (loss), net of tax
Foreign currency translation adjustments									(14,080)	(3,830)	790
Unrealized gains (losses) gains on available for sale securities									(28)	(31)	(21)
Net current-period other comprehensive loss									(14,108)	(3,861)	(2,013)
Comprehensive income (loss)									$ (35,990)	33,090	$ 27,581
Scenario, Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)										39,881
Other comprehensive income (loss), net of tax
Foreign currency translation adjustments										(3,830)
Unrealized gains (losses) gains on available for sale securities										(31)
Net current-period other comprehensive loss										(3,861)
Comprehensive income (loss)										36,020
Unrecorded Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)										(2,930)
Other comprehensive income (loss), net of tax
Comprehensive income (loss)										$ (2,930)

Restatement of Consolidated Bal

Restatement of Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 28,962	$ 55,633	$ 42,332	$ 27,687
Short-term investments	20,060	18,473
Accounts receivable, net of chargebacks and other deductions	51,425	42,780
Inventories, net	76,453	61,781
Due from related party	2,678	2,156
Prepaid expenses and other current assets	7,388	5,560
Total current assets	191,592	186,383
Property, plant, and equipment, net	19,761	71,153
Investment in joint ventures	7,108	4,539	2,063
Goodwill	25,184	28,155
Intangible assets, net	53,166	65,575
Non-current deferred tax assets	50,808	23,778
Other assets	2,113	375
Total assets	349,732	379,958	310,208
Current liabilities:
Accounts payable	43,703	32,710
Due to related party	13,754	8,079
Accrued profit sharing	7,582	10,684
Accrued liabilities	15,706	19,346
Current portion of deferred purchase consideration		8,725
Current portion of long-term debt	0	508
Notes payable		5,499
Total current liabilities	83,655	85,551
Long term liabilities:
Long-term debt	1,623	1,945
Deferred income taxes	12,021	15,706
Other long-term liabilities	1,340	2,954
Total liabilities	98,639	106,156
Stockholders' equity:
Common stock - $0.01 par value, 100,000,000 authorized, and 32,801,896 and 31,976,661 outstanding at December 31, 2015 and December 31, 2014, respectively	328	320
Additional paid-in capital	367,235	353,962
Accumulated other comprehensive income (loss)	(17,482)	(3,374)	487	2,500
Accumulated deficit	(98,988)	(77,106)
Total stockholders' equity	251,093	273,802	236,026	$ 131,855
Total liabilities and stockholders' equity	$ 349,732	379,958
Scenario, Previously Reported
Current assets:
Cash and cash equivalents		55,633	$ 42,332
Short-term investments		18,473
Accounts receivable, net of chargebacks and other deductions		42,780
Inventories, net		61,781
Due from related party		2,156
Prepaid expenses and other current assets		5,560
Total current assets		186,383
Property, plant, and equipment, net		71,153
Investment in joint ventures		4,539
Goodwill		28,155
Intangible assets, net		65,575
Non-current deferred tax assets		25,308
Other assets		375
Total assets		381,488
Current liabilities:
Accounts payable		32,710
Due to related party		8,079
Accrued profit sharing		10,684
Accrued liabilities		19,346
Current portion of deferred purchase consideration		8,725
Current portion of long-term debt		508
Notes payable		5,499
Total current liabilities		85,551
Long term liabilities:
Long-term debt		1,945
Deferred income taxes		15,706
Other long-term liabilities		2,534
Total liabilities		105,736
Stockholders' equity:
Common stock - $0.01 par value, 100,000,000 authorized, and 32,801,896 and 31,976,661 outstanding at December 31, 2015 and December 31, 2014, respectively		320
Additional paid-in capital		352,982
Accumulated other comprehensive income (loss)		(3,374)
Accumulated deficit		(74,176)
Total stockholders' equity		275,752
Total liabilities and stockholders' equity		381,488
Unrecorded Adjustment
Current assets:
Non-current deferred tax assets		(1,530)
Total assets		(1,530)
Long term liabilities:
Other long-term liabilities		420
Total liabilities		420
Stockholders' equity:
Additional paid-in capital		980
Accumulated deficit		(2,930)
Total stockholders' equity		(1,950)
Total liabilities and stockholders' equity		$ (1,530)

Restatement of Consolidated B61

Restatement of Consolidated Balance Sheet (Parenthetical) (Detail) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Condensed Financial Information of Subsidiaries Disclosure [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized shares	100,000,000	100,000,000
Common stock, outstanding shares	32,801,896	31,976,661

Restatement of Consolidated S62

Restatement of Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands	Sep. 16, 2013	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net income (loss)		$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization										13,681	9,524	7,074
Stock-based compensation										3,836	2,683	5,293
Equity in net income of joint ventures										(2,569)	(3,987)	(2,395)
Dividends from unconsolidated joint ventures											1,511	4,318
Gain on previously held equity interest										0	0	(2,936)
Deferred income taxes, net										(28,025)	(23,732)
Other										1,117	(1,180)	(115)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable										(9,250)	(16,442)	8,578
Inventories, net										(20,564)	(1,713)	3,053
Prepaid expenses and other current assets										(2,571)	2,171	(3,466)
Due from related party										(522)	(1,208)	(6,924)
Accounts payable and other accrued liabilities										14,068	17,621	7,477
Net cash provided by (used in) operating activities										(7,523)	22,199	49,551
Cash flows from investing activities
Capital expenditures										(6,711)	(4,242)	(1,103)
Acquisition of business, net of cash acquired										(11,785)	(86,467)	(12,996)
Purchases of investments										(13,212)	(87,171)	(275,198)
Sale of investments										11,420	181,352	196,728
Purchase of product rights										(1,707)	(4,404)	(5,174)
Other											0	586
Net cash (used in) provided by investing activities										(21,995)	(932)	(97,157)
Cash flows from financing activities
Increase (reduction) in short-term borrowings										(5,189)	1,152
Repayment of long-term debt										(471)	(10,420)	(8,961)
Proceeds from issuance of common stock, net of issuance costs	$ 70,580									9,345	1,023	71,247
Payment of deferred financing costs										(274)	(285)	(28)
Excess tax benefits on stock option exercises										92	980
Net cash (used in) provided by financing activities										3,503	(7,550)	62,258
Effect of exchange rate movements in cash										(656)	(416)	(7)
Net increase (decrease) in cash and cash equivalents										(26,671)	13,301	14,645
Cash and cash equivalents, at beginning of period					55,633				42,332	55,633	42,332	27,687
Cash and cash equivalents, at end of period		$ 28,962				55,633				28,962	55,633	42,332
Supplemental disclosure of cash flow information
Acquisition of property, plant and equipment in accounts payable										(856)	934
Cash paid for interest										414	1,361	652
Cash paid for taxes										4,340	2,555
Scenario, Previously Reported
Cash flows from operating activities
Net income (loss)											39,881
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization											9,524
Stock-based compensation											2,683
Equity in net income of joint ventures											(3,987)
Dividends from unconsolidated joint ventures											1,511
Gain on previously held equity interest											0
Deferred income taxes, net											(26,242)
Other											(200)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable											(16,442)
Inventories, net											(1,713)
Prepaid expenses and other current assets											2,171
Due from related party											(1,208)
Accounts payable and other accrued liabilities											17,201
Net cash provided by (used in) operating activities											23,179
Cash flows from investing activities
Capital expenditures											(4,242)
Acquisition of business, net of cash acquired											(86,467)
Purchases of investments											(87,171)
Sale of investments											181,352
Purchase of product rights											(4,404)
Other											0
Net cash (used in) provided by investing activities											(932)
Cash flows from financing activities
Increase (reduction) in short-term borrowings											1,152
Repayment of long-term debt											(10,420)
Proceeds from issuance of common stock, net of issuance costs											1,023
Payment of deferred financing costs											(285)
Net cash (used in) provided by financing activities											(8,530)
Effect of exchange rate movements in cash											(416)
Net increase (decrease) in cash and cash equivalents											13,301
Cash and cash equivalents, at beginning of period					$ 55,633				$ 42,332	$ 55,633	42,332
Cash and cash equivalents, at end of period						$ 55,633					55,633	$ 42,332
Supplemental disclosure of cash flow information
Acquisition of property, plant and equipment in accounts payable											934
Cash paid for interest											1,361
Cash paid for taxes											2,555
Unrecorded Adjustment
Cash flows from operating activities
Net income (loss)											(2,930)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Gain on previously held equity interest											0
Deferred income taxes, net											2,510
Other											(980)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts payable and other accrued liabilities											420
Net cash provided by (used in) operating activities											(980)
Cash flows from investing activities
Other											0
Cash flows from financing activities
Excess tax benefits on stock option exercises											980
Net cash (used in) provided by financing activities											$ 980

Assets Held for Sale - Addition

Assets Held for Sale - Additional Information (Detail) - SCP - USD ($) $ in Thousands	Feb. 03, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of SCP long-lived assets		$ 45,158
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of outstanding shares to be sold	100.00%
Outstanding shares exchange amount	$ 500

Condensed Balance Sheet Informa

Condensed Balance Sheet Information (Detail) - SCP $ in Thousands	Dec. 31, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 8
Inventories, net	3,529
Property, plant, and equipment, net	500
Other assets	589
Total assets of SCP as held for sale in the Balance Sheet	4,626
Accounts payable	722
Accrued liabilities	1,876
Other liabilities	312
Total liabilities of SCP as held for sale in the Balance Sheet	$ 2,910

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) CAD in Thousands, $ in Thousands	Aug. 05, 2015USD ($)	Dec. 19, 2014USD ($)Product_Right	Oct. 01, 2014USD ($)	Oct. 01, 2014CAD	Dec. 12, 2013USD ($)	Jun. 04, 2013USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015CAD	Sep. 30, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Product_Right	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Oct. 01, 2014CAD
Business Acquisition [Line Items]
Percentage of equity interest acquired						50.00%
Goodwill											$ 25,184	$ 28,155
Acquisition related installment payment obligation made											11,785	86,467	$ 12,996
Gain on previously held equity interest											0	0	2,936
Reclassification of cumulative currency translation gain													2,782
Business acquisition related cost											$ 2,838	1,069
Mustafa NevzatIlac Sanayii A S
Business Acquisition [Line Items]
Business acquisition, purchase price	$ 3,000
Number of products rights acquired | Product_Right											3
Weighted average life of these three acquired products rights											84 months
Sagent Agila LLC
Business Acquisition [Line Items]
Business acquisition, purchase price		$ 1,760			$ 3,400
Business acquisition, gross consideration paid		$ 1,155			3,200
Gain on previously held equity interest					3,400
Number of products rights acquired | Product_Right		3
Contingent consideration		$ 605			200
Gain on sale of joint venture partners		1,760
Fair value of contingent consideration		$ 605			$ 200
Omega
Business Acquisition [Line Items]
Business acquisition, purchase price			$ 82,693	CAD 92,768
Post closing adjustment cost			$ (170)	CAD (191)			$ (215)	CAD (241)
Percentage of equity interest acquired			100.00%											100.00%
Goodwill			$ 22,842
Post-closing adjustment											$ 649
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual												8,561
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual												$ (2,126)
Business acquisition, gross consideration paid			82,863
Cash			3
Inventory			14,014
Prepaid and other current assets			1,295
Property, plant and equipment			14,307											CAD 16,050
Accounts payable			$ 2,410
SCP
Business Acquisition [Line Items]
Business acquisition, purchase price						$ 25,000					39,939
Percentage of equity interest acquired						50.00%
Goodwill											6,038
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual													344
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual													$ 6,137
Business acquisition, gross consideration paid						$ 10,000					10,000
Business acquisition, fair value of future payment						$ 13,836					13,836
Acquisition related installment payment obligation made							$ 9,000		$ 3,500	$ 2,500
Gain on previously held equity interest											2,936
Reclassification of cumulative currency translation gain											2,782
Business acquisition related cost											479
Cash											2,704
Inventory											2,396
Prepaid and other current assets											196
Property, plant and equipment											56,654
Accounts payable											19,095
Accrued compensation and other liabilities											$ 8,954

Purchase Consideration Related

Purchase Consideration Related to Acquisition (Detail) CAD in Thousands, $ in Thousands	Oct. 01, 2014USD ($)	Oct. 01, 2014CAD	Jun. 04, 2013USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015CAD	Dec. 31, 2015USD ($)
Omega
Schedule of Business Acquisitions, Purchase Price [Line Items]
Cash	$ 82,863
Net working capital adjustments receivable from the sellers	(170)	CAD (191)		$ (215)	CAD (241)
Total purchase consideration	$ 82,693	CAD 92,768
SCP
Schedule of Business Acquisitions, Purchase Price [Line Items]
Cash			$ 10,000			$ 10,000
Present value of remaining purchase consideration			13,836			13,836
Previously held equity interest						15,949
Gain on remeasurement of previously held equity interest in KSCP						154
Total purchase consideration			$ 25,000			$ 39,939

Allocation of Purchase Price (D

Allocation of Purchase Price (Detail) CAD in Thousands, $ in Thousands	Dec. 31, 2015USD ($)	Aug. 05, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 19, 2014USD ($)	Oct. 01, 2014USD ($)	Oct. 01, 2014CAD	Dec. 12, 2013USD ($)
Business Acquisition [Line Items]
Goodwill	$ 25,184		$ 28,155
Omega
Business Acquisition [Line Items]
Cash					$ 3
Accounts receivable, net					3,419
Inventory					14,014
Prepaid and other current assets					1,295
Property, plant and equipment					14,307	CAD 16,050
Definite-lived intangible asset					49,918
In-process research and development					7,666
Goodwill					22,842
Accounts payable					(2,410)
Other accrued liabilities					(4,090)
Long-term debt and notes payable					(7,095)
Deferred income tax liabilities					(17,176)
Total allocation of fair value					$ 82,693
SCP
Business Acquisition [Line Items]
Cash	2,704
Inventory	2,396
Prepaid and other current assets	196
Property, plant and equipment	56,654
Goodwill	6,038
Accounts payable	(19,095)
Acquired tangible assets, net of assumed liabilities	33,901
Total allocation of fair value	$ 39,939
Mustafa NevzatIlac Sanayii A S
Business Acquisition [Line Items]
Definite-lived intangible asset		$ 3,000
Total allocation of fair value		$ 3,000
Sagent Agila LLC
Business Acquisition [Line Items]
Definite-lived intangible asset				$ 720			$ 2,180
In-process research and development				1,040			1,220
Total allocation of fair value				$ 1,760			$ 3,400

Consolidated Pro Forma Operatio

Consolidated Pro Forma Operations Results in Acquisition (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Omega
Business Acquisition [Line Items]
Net revenues	$ 312,853
Net income	$ 35,462
Diluted income per common share	$ 1.08
SCP
Business Acquisition [Line Items]
Net revenues		$ 244,750
Net income		$ 25,881
Diluted income per common share		$ 0.86

Investments (Detail)

Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]
Cost basis	$ 49,090	$ 74,146
Unrealized gains		1
Unrealized losses	(68)	(41)
Carrying value	49,022	74,106
Cash and cash equivalents	28,962	55,633	$ 42,332	$ 27,687
Short-term investments	20,060	18,473
Cash
Schedule of Available-for-sale Securities [Line Items]
Cost basis	15,124	42,494
Carrying value	15,124	42,494
Cash and cash equivalents	15,124	42,494
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Cost basis	13,838	13,139
Carrying value	13,838	13,139
Cash and cash equivalents	13,838	13,139
Corporate bonds and notes
Schedule of Available-for-sale Securities [Line Items]
Cost basis	20,128	18,513
Unrealized gains		1
Unrealized losses	(68)	(41)
Carrying value	20,060	18,473
Short-term investments	$ 20,060	$ 18,473

Investments with Continuous Unr

Investments with Continuous Unrealized Losses for Less Than Twelve Months and Related Fair Values (Detail) - Corporate bonds and notes - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Fair value	$ 20,060	$ 16,468
Unrealized losses	$ (68)	$ (41)

Cost and Estimated Current Fair

Cost and Estimated Current Fair Value of Fixed-Income Securities (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in one year or less, cost basis	$ 9,417
Between one and five years, cost basis	10,710
Due in one year or less, Estimated fair value	9,406
Between one and five years, Estimated fair value	$ 10,654

Accounts Receivable and Conce72

Accounts Receivable and Concentration of Credit Risk - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)Customer	Dec. 31, 2014USD ($)Customer	Dec. 31, 2013Customer
Accounts and Other Receivables [Line Items]
Number of wholesalers | Customer	3	3	3
Reserve for accounts receivable | $	$ 43	$ 1,433
Sales Revenue, Net | Credit Concentration Risk
Accounts and Other Receivables [Line Items]
Concentration of credit risk	78.00%	85.00%	84.00%
Accounts Receivable | Credit Concentration Risk
Accounts and Other Receivables [Line Items]
Concentration of credit risk	89.00%	90.00%

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 7,655	$ 13,051
Work in process	433	2,012
Finished goods	73,365	49,960
Inventory reserve	(5,000)	(3,242)
Inventory, Net, Total	76,453	61,781
Approved
Inventory [Line Items]
Raw materials	4,855	10,203
Work in process	433	2,012
Finished goods	73,365	49,960
Inventory reserve	(5,000)	(3,242)
Inventory, Net, Total	73,653	58,933
Pending Regulatory Approval
Inventory [Line Items]
Raw materials	2,800	2,848
Inventory, Net, Total	$ 2,800	$ 2,848

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 7,655	$ 13,051
Pending Regulatory Approval
Inventory [Line Items]
Raw materials	$ 2,800	$ 2,848

Property, Plant and Equipment75

Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment before depreciation	$ 23,583	$ 78,423
Less: accumulated depreciation	(3,822)	(7,270)
Property, plant and equipment after depreciation	19,761	71,153
Land and land improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment before depreciation	1,102	3,519
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment before depreciation	6,713	26,605
Machinery, equipment, furniture and fixtures, and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment before depreciation	9,233	42,124
Construction in process
Property, Plant and Equipment [Line Items]
Property, plant and equipment before depreciation	$ 6,535	$ 6,175

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Detail) CAD in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Oct. 01, 2014USD ($)	Oct. 01, 2014CAD
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 5,815	$ 4,355	$ 1,620
Omega
Property, Plant and Equipment [Line Items]
Property, plant and equipment				$ 14,307	CAD 16,050

Investment in Sagent Agila - Ad

Investment in Sagent Agila - Additional Information (Detail)	Dec. 31, 2015
Sagent Agila LLC
Schedule of Equity Method Investments [Line Items]
Joint venture, ownership interest percentage	50.00%

Changes in Investment of Sagent

Changes in Investment of Sagent Agila (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Investment at beginning of year	$ 4,539	$ 2,063
Equity in net income (loss) of joint ventures	(2,569)	(3,987)	$ (2,395)
Dividend paid		(1,511)	(4,318)
Investment at end of year	7,108	4,539	2,063
Sagent Agila LLC
Schedule of Equity Method Investments [Line Items]
Investment at beginning of year	4,539	2,063
Equity in net income (loss) of joint ventures	2,569	3,987
Dividend paid		(1,511)
Investment at end of year	$ 7,108	$ 4,539	$ 2,063

Condensed Statement of Operatio

Condensed Statement of Operations Information (Detail) - Sagent Agila LLC - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Net revenues	$ 9,063	$ 8,093	$ 16,927
Gross profit	5,140	6,321	5,454
Net income	$ 5,138	$ 7,975	$ 8,440

Condensed Statement of Balance

Condensed Statement of Balance Sheet (Detail) - Sagent Agila LLC - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Current assets	$ 17,036	$ 11,333
Noncurrent assets	303	360
Total assets	17,339	11,693
Current liabilities	3,144	2,636
Long-term liabilities	0	0
Stockholders' equity	14,195	9,057
Total liabilities and stockholders' equity	$ 17,339	$ 11,693

Schedule of Goodwill by Reporta

Schedule of Goodwill by Reportable Segment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill	$ 25,184	$ 28,155
Sagent US
Goodwill [Line Items]
Goodwill	6,038	6,038
Omega
Goodwill [Line Items]
Goodwill	$ 19,146	$ 22,117

Goodwill and Intangible asset82

Goodwill and Intangible assets, net - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)Product_Right	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of products comprising product licensing rights intangible asset | Product_Right	21
Weighted-average period prior to next extension or renewal of intangible asset	4 years 3 months 18 days
Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill		$ 22,842,000
Foreign Currency Translation Impact | Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill	$ (3,620,000)	(725,000)
Post-closing Adjustments | Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill	649,000
Product Licensing Rights
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 394,000	807,000	$ 529,000
Weighted-average period prior to next extension or renewal of intangible asset	53 months
Product Development Rights
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 2,908,000	1,637,000	$ 3,980,000
Purchased Product Rights And Other
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,183,000	$ 1,380,000
Weighted average remaining life of purchased product rights and other definite lived intangibles	110 months
In-process Research and Development | Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill	$ 864,000
Post-closing Working Capital Adjustment | Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill	215,000
Impairments | Omega
Finite-Lived Intangible Assets [Line Items]
Increase (decrease) in goodwill	$ 0

Schedule of Intangible Assets (

Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, Gross carrying amount	$ 53,661	$ 60,143
Intangible assets, Gross carrying amount	61,251	69,828
Definite-lived intangible assets, Accumulated amortization	(8,085)	(4,253)
Definite-lived intangible assets, net	45,576	55,890
Intangible assets, net	53,166	65,575
Product Licensing Rights
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, Gross carrying amount	4,533	4,707
Definite-lived intangible assets, Accumulated amortization	(2,998)	(2,878)
Definite-lived intangible assets, net	1,535	1,829	$ 1,690
Product Development Rights
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, Gross carrying amount	2,890	4,191
Definite-lived intangible assets, net	2,890	4,191	3,252
Purchased Product Rights And Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, Gross carrying amount	46,238	51,245
Definite-lived intangible assets, Accumulated amortization	(5,087)	(1,375)
Definite-lived intangible assets, net	41,151	49,870	2,164
IPR&D
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Indefinite-lived IPR&D, Intangible assets, net	$ 7,590	$ 9,685	$ 1,220

Movements in Intangible Assets

Movements in Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets Disclosure [Line Items]
Beginning Balance	$ 55,890
Ending Balance	45,576	$ 55,890
Product Licensing Rights
Intangible Assets Disclosure [Line Items]
Beginning Balance	1,829	1,690
Acquisition of product rights	100	946
Amortization	(394)	(807)	$ (529)
Ending Balance	1,535	1,829	1,690
Product Development Rights
Intangible Assets Disclosure [Line Items]
Beginning Balance	4,191	3,252
Acquisition of product rights	1,607	2,576
Amortization	(2,908)	(1,637)	(3,980)
Ending Balance	2,890	4,191	3,252
Purchased Product Rights And Other
Intangible Assets Disclosure [Line Items]
Beginning Balance	49,870	2,164
Acquisition of product rights	3,000
Amortization	(4,183)	(1,380)
Foreign currency movements	(7,536)	(1,552)
Ending Balance	41,151	49,870	2,164
Purchased Product Rights And Other | Omega
Intangible Assets Disclosure [Line Items]
Acquisition of product rights		49,918
Purchased Product Rights And Other | Sagent Agila product acquisitions
Intangible Assets Disclosure [Line Items]
Acquisition of product rights		720
IPR&D
Intangible Assets Disclosure [Line Items]
Balance at January 1	9,685	1,220
Foreign currency movements	(1,231)	(241)
Balance at December 31	$ 7,590	9,685	$ 1,220
IPR&D | Omega
Intangible Assets Disclosure [Line Items]
Acquisition of product rights		7,666
IPR&D | Sagent Agila product acquisitions
Intangible Assets Disclosure [Line Items]
Acquisition of product rights		$ 1,040

Schedule of Estimate Amortizati

Schedule of Estimate Amortization Expense over Each of the Next Five Years (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
For the year ending December 31, 2016	$ 7,132
For the year ending December 31, 2017	4,223
For the year ending December 31, 2018	4,192
For the year ending December 31, 2019	4,121
For the year ending December 31, 2020	$ 3,971

Accrued Liabilities (Detail)

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Payroll and employee benefits	$ 6,512	$ 9,329
Sales and marketing	7,308	6,964
Taxes payable	131	1,040
Other accrued liabilities	1,755	2,013
Accrued Liabilities, Total	$ 15,706	$ 19,346

Debt - Additional Information (

Debt - Additional Information (Detail) ¥ in Thousands

Jan. 07, 2016USD ($)

Oct. 01, 2015USD ($)MortgageLoan

Oct. 01, 2015CAD

Jul. 31, 2015CAD

Oct. 31, 2014USD ($)

Oct. 01, 2014USD ($)

Jan. 02, 2014USD ($)

Jan. 02, 2014CNY (¥)

Jun. 04, 2013USD ($)Contract

Feb. 28, 2013USD ($)

Jun. 30, 2011USD ($)

Aug. 31, 2010USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Jan. 07, 2016CAD

Oct. 01, 2015CADMortgageLoan

Oct. 01, 2014CAD

Dec. 31, 2013CNY (¥)

Jun. 30, 2011CNY (¥)

Aug. 31, 2010CNY (¥)

Line of Credit Facility [Line Items]

Loan contracts assumed in a business combination

$ 6,069,000

$ 6,069,000

$ 13,613,000

¥ 37,000

¥ 83,000

Period of loan contract

5 years

5 years

Percentage of remaining equity interest acquired

50.00%

Number of loan contracts | Contract

2

Interest rate adjustment frequency period

3 months

Outstanding ABC loan amount

$ 10,333,000

¥ 63,000

Interest rate

6.00%

Debt covenant, projected revenue below which triggers acceleration of repayment

50.00%

Credit Facility One

Line of Credit Facility [Line Items]

Debt covenant, maximum liquidity ratio that triggers acceleration of repayment

70.00%

Credit Facility Two

Line of Credit Facility [Line Items]

Debt covenant, maximum liquidity ratio that triggers acceleration of repayment

80.00%

Omega

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 7,309,000

CAD 8,200,000

Credit facility, interest rate

3.50%

Percentage of remaining equity interest acquired

100.00%

100.00%

Number of mortgage loans | MortgageLoan

5

5

Omega | Prime Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

0.50%

Omega | Floating Rate

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 6,239,000

CAD 7,000,000

Credit facility

1,364,000

1,530,000

Silicon Valley Bank Loan And Security Agreement

Line of Credit Facility [Line Items]

Loan and security agreement date

Sep. 23, 2013

Mortgage Loans | Omega | Prime Rate

Line of Credit Facility [Line Items]

Interest rate

5.00%

5.00%

Minimum | Silicon Valley Bank Loan And Security Agreement

Line of Credit Facility [Line Items]

Minimum cash requirement

$ 30,000,000

Minimum | Mortgage Loans | Omega

Line of Credit Facility [Line Items]

Monthly mortgages installments

$ 62,000

CAD 70,000

Minimum | Mortgage Loans | Omega | Prime Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

0.00%

0.00%

Maximum | Mortgage Loans | Omega

Line of Credit Facility [Line Items]

Monthly mortgages installments

$ 1,114,000

CAD 1,250,000

Maximum | Mortgage Loans | Omega | Prime Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.50%

1.50%

Subsequent Event | Canadian Term Loans

Line of Credit Facility [Line Items]

Commitment fee rate

0.25%

Fixed charge coverage ratio

100.00%

100.00%

Subsequent Event | Prime Rate | Canadian Term Loans

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.25%

Subsequent Event | CDOR | Canadian Term Loans

Line of Credit Facility [Line Items]

Basis spread on variable rate

2.25%

Subsequent Event | Omega | Term Loan

Line of Credit Facility [Line Items]

Amount available under credit facility | CAD

CAD 30,000,000

Demand Loan | Omega

Line of Credit Facility [Line Items]

Principal amount of demand loan | CAD

CAD 3,000,000

Effective interest rate

4.75%

Debt collateral amount | CAD

CAD 3,000,000

Additional security interest percentage

20.00%

Interest rate per annum

4.75%

Maturity date

2014-11

Debt instrument extended maturity date

2015-01

2015-01

Demand Loan | Omega | Prime Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.75%

Revolving Credit Facility

Line of Credit Facility [Line Items]

Repayment of outstanding balance of credit facility

$ 10,300,000

¥ 63,000

Revolving Credit Facility | Omega

Line of Credit Facility [Line Items]

Credit facility, interest rate

4.00%

4.00%

Credit facility

$ 238,000

CAD 267,000

Debt collateral amount

$ 891,000

CAD 1,000,000

Revolving Credit Facility | Omega | Prime Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.00%

1.00%

Revolving Credit Facility | JPMorgan Chase Revolving Credit Loan Facility

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 80,000,000

Amount available under additional revolving credit facility

$ 25,000,000

Debt coverage ratio

100.00%

Agreement maturity date

Oct. 31, 2019

Commitment fee on undrawn amounts

0.25%

Credit facility, interest rate

10.00%

Credit facility

$ 0

Line of Credit Facility, Remaining Borrowing Capacity

79,900,000

Revolving Credit Facility | JPMorgan Chase Revolving Credit Loan Facility | Eurodollar

Line of Credit Facility [Line Items]

Basis spread on variable rate

2.00%

Revolving Credit Facility | JPMorgan Chase Revolving Credit Loan Facility | Base Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.00%

Revolving Credit Facility | Silicon Valley Bank Loan And Security Agreement

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 40,000,000

Agreement maturity date

Feb. 13, 2016

Commitment fee on undrawn amounts

0.30%

Termination fees

$ 1,050,000

Revolving Credit Facility | Silicon Valley Bank Loan And Security Agreement | Eurodollar

Line of Credit Facility [Line Items]

Basis spread on variable rate

2.50%

Revolving Credit Facility | Silicon Valley Bank Loan And Security Agreement | Base Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.50%

Revolving Credit Facility | Minimum | JPMorgan Chase Revolving Credit Loan Facility

Line of Credit Facility [Line Items]

Debt coverage ratio

100.00%

Revolving Credit Facility | Maximum | JPMorgan Chase Revolving Credit Loan Facility

Line of Credit Facility [Line Items]

Line of credit availability to trigger debt covenants

$ 8,000,000

Revolving Credit Facility | Subsequent Event

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 80,000,000

CAD 10,000,000

Revolving Credit Facility | Subsequent Event | Eurodollar

Line of Credit Facility [Line Items]

Basis spread on variable rate

2.00%

Revolving Credit Facility | Subsequent Event | Base Rate

Line of Credit Facility [Line Items]

Basis spread on variable rate

1.00%

Letter of Credit | Omega

Line of Credit Facility [Line Items]

Amount available under credit facility

1,782,000

2,000,000

Currency Risk | Omega

Line of Credit Facility [Line Items]

Amount available under credit facility

$ 1,070,000

CAD 1,200,000

Operating Credit Facility | Demand Loan | Omega

Line of Credit Facility [Line Items]

Debt collateral amount

$ 7,354,000

CAD 8,250,000

Debt - Debt Maturities by Year

Debt - Debt Maturities by Year (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
2,016	$ 0
2,017	0
2,018	0
2,019	1,623
2,020	0
2021 and thereafter	0
Total long-term debt	1,623
Less: Current maturities of long-term debt	0	$ 508
Long-term portion of long-debt	1,623	$ 1,945
Total long-term debt	$ 1,623

Summary of Assets and Liabiliti

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and liabilities measured at fair value on a recurring basis - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 33,898	$ 31,652
Contingent purchase consideration	50	605
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	13,838	13,139
Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	20,060	18,513
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	33,898	18,513
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	13,838	13,139
Quoted prices in active markets for identical assets (Level 1) | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	13,838	13,139
Quoted prices in active markets for identical assets (Level 1) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	13,838
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	20,060	18,513
Significant other observable inputs (Level 2) | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	20,060	18,513
Significant other observable inputs (Level 2) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	20,060	18,513
Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase consideration	$ 50	$ 605

Summary of Contingent Purchase

Summary of Contingent Purchase Consideration Measured Using Significant Unobservable Inputs (Level 3) (Detail) - Contingent Consideration Liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 605
Issuance of contingent purchase consideration	0
Change in fair value of contingent purchase consideration	(555)	$ (555)
Payment of contingent purchase consideration	0
Balance at end of period	$ 50	$ 605

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Contingent Consideration Liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of contingent purchase consideration	$ (555)	$ (555)

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
401(k) Plan, matching contribution percentage	50.00%
401(k) Plan, maximum contribution percentage	6.00%
401(k) Plan, employer contribution vesting period	3 years
401(k) Plan, total matching contribution	$ 430,000	$ 391,000	$ 338,000
401(k) Plan, employer discretionary contribution	$ 0	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 16, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Common stock shares authorized		100,000,000	100,000,000
Common stock share reserved for outstanding stock options		5,892,670	5,892,670
Issuance of common stock (in shares)	3,542,470
Issuance of common stock, value	$ 75,277			$ 70,580
Stock issued during period, share price	$ 21,250
Proceeds from issuance of shares	$ 70,580	$ 9,345	$ 1,023	$ 71,247

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Currency translation adjustment, net of tax	$ (17,414)	$ (3,334)	$ 496
Unrealized gains (losses) on available for sale securities, net of tax	(68)	(40)	(9)
Total accumulated other comprehensive income (loss)	$ (17,482)	$ (3,374)	$ 487	$ 2,500

Component of Accumulated Other

Component of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ (3,374)	$ 487	$ 2,500
Other comprehensive income (loss) before reclassifications	(14,108)	(3,861)	769
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	(2,782)
Net current-period other comprehensive loss	(14,108)	(3,861)	(2,013)
Ending balance	(17,482)	(3,374)	487
Currency translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(3,334)	496	2,488
Other comprehensive income (loss) before reclassifications	(14,080)	(3,830)	790
Amounts reclassified from accumulated other comprehensive income (loss)			(2,782)
Net current-period other comprehensive loss	(14,080)	(3,830)	(1,992)
Ending balance	(17,414)	(3,334)	496
Unrealized gains (losses) on available for sale securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(40)	(9)	12
Other comprehensive income (loss) before reclassifications	(28)	(31)	(21)
Net current-period other comprehensive loss	(28)	(31)	(21)
Ending balance	$ (68)	$ (40)	$ (9)

Accumulated Other Comprehensi96

Accumulated Other Comprehensive Income (Loss) - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Amounts reclassified from accumulated other comprehensive income (loss)	$ 0	$ 0	$ 2,782

Amounts Reclassified Out of Eac

Amounts Reclassified Out of Each Component of Accumulated Other Comprehensive Income (Detail) - Reclassification out of Accumulated Other Comprehensive Income $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Sale of Equity Investments	$ 2,782
Currency translation adjustment
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Sale of Equity Investments	$ 2,782

Earning Per Share - Additional

Earning Per Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Anti-dilutive share excluded from the calculation of diluted earnings	1,859,247	705,150	1,194,717

Schedule of Calculation of Nume

Schedule of Calculation of Numerator and Denominator in Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Basic and dilutive numerator:
Net income (loss), as reported	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Denominator:
Weighted-average common shares outstanding-basic (in thousands)	32,793	32,747	32,161	32,043	31,945	31,895	31,873	31,814	32,439	31,882	29,213
Net effect of dilutive securities: Stock options and restricted stock										863	724
Weighted-average common shares outstanding-diluted (in thousands)	32,793	32,747	32,161	32,043	33,031	32,960	32,665	32,614	32,439	32,745	29,937
Net income (loss) per common share (basic)	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.84	$ 0.06	$ 0.10	$ 0.16	$ (0.67)	$ 1.16	$ 1.01
Net income (loss) per common share (diluted)	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.81	$ 0.06	$ 0.09	$ 0.16	$ (0.67)	$ 1.13	$ 0.99

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock compensation expense	$ 1,901
Weighted-average remaining contractual lives of options outstanding		6 years 7 months 6 days	6 years 7 months 6 days	7 years 2 months 12 days
Weighted-average remaining contractual lives of options exercisable		5 years 3 months 18 days	5 years 10 months 24 days	6 years 6 months
Intrinsic value of stock options exercised		$ 9,169	$ 3,147	$ 1,860
Fair value of options vested		2,900	$ 3,327	$ 5,036
Unrecognized stock-based compensation		$ 5,853
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards, vesting period		4 years
Stock options, expiration period		10 years
Unrecognized stock-based compensation, average period recognized		1 year 4 months 24 days
Restricted Stock Awards (RSAs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation related to restricted stock		$ 2,770
Unrecognized stock-based compensation, average period recognized		29 months
Equity Incentive Plan Twenty Zero Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive compensation plan, shares authorized		2,475,184
Incentive compensation plan, shares available for grant		417,280
Equity Incentive Plan Twenty Eleven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive compensation plan, shares authorized		4,000,000
Incentive compensation plan, shares available for grant		2,215,631

Restricted Stock Activity (Deta

Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Weighted-Average Grant Date Fair Value
Granted	$ 10.92	$ 11.81	$ 9.31
Restricted Stock Awards (RSAs)
Restricted stock
Beginning Balance	128,209
Granted	140,971
Vested	(40,496)
Forfeited	(48,476)
Ending Balance	180,208	128,209
Weighted-Average Grant Date Fair Value
Beginning Balance	$ 19.32
Granted	24.59
Vested	19.42
Forfeited	22.10
Ending Balance	$ 22.91	$ 19.32

Weighted-Average Assumptions Us

Weighted-Average Assumptions Used in Calculating Estimated Values (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk free interest rate	1.74%	1.92%	1.24%
Expected life	6 years	6 years	6 years
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	52.00%	61.00%	62.00%
Fair value at grant date	$ 10.92	$ 11.81	$ 9.31

Stock Options Outstanding Veste

Stock Options Outstanding Vested and Expected to Vest (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and expected to vest, Number of shares | shares	1,621,346
Vested and expected to vest, Weighted-Average Exercise Price | $ / shares	$ 16.61
Vested and expected to vest, Weighted-Average Remaining Contractual Term	6 years 6 months
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 4,521	[1]
Options Vested
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and expected to vest, Number of shares | shares	1,021,292
Vested and expected to vest, Weighted-Average Exercise Price | $ / shares	$ 12.96
Vested and expected to vest, Weighted-Average Remaining Contractual Term	5 years 3 months 18 days
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 4,503	[1]
Options Expected To Vest
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and expected to vest, Number of shares | shares	600,054
Vested and expected to vest, Weighted-Average Exercise Price | $ / shares	$ 22.27
Vested and expected to vest, Weighted-Average Remaining Contractual Term	8 years 6 months
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 18	[1]
[1]	The Aggregate Intrinsic Value amounts represent the difference between the exercise price and $15.91, the fair value of our stock on December 31, 2015, for in-the-money options.

Stock Options Outstanding Ve104

Stock Options Outstanding Vested and Expected to Vest (Parenthetical) (Detail)	Dec. 31, 2015$ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Fair value of stock	$ 15.91

Stock Option Activity (Detail)

Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance, Options Outstanding	2,543,362
Granted	411,743
Exercised	(794,528)
Forfeited	(481,538)
Ending Balance, Options Outstanding	1,679,039	2,543,362
Balance, Exercisable Options	1,021,292	1,622,212
Beginning Balance, Options Outstanding, Weighted-Average Exercise Price	$ 14.71
Granted	25.11
Exercised	12.32
Forfeited	20.93
Ending Balance, Options Outstanding, Weighted-Average Exercise Price	16.61	$ 14.71
Balance, Exercisable Options, Weighted-Average Exercise Price	$ 12.96	$ 12.04

Schedule of Net Revenue by Prod

Schedule of Net Revenue by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Net revenue by product Line	$ 83,107	$ 75,199	$ 77,345	$ 82,645	$ 83,561	$ 65,359	$ 69,194	$ 70,869	$ 318,296	$ 288,983	$ 244,750
Anti-infective
Product Information [Line Items]
Net revenue by product Line									128,517	102,078	90,604
Critical care
Product Information [Line Items]
Net revenue by product Line									120,157	87,143	65,612
Oncology
Product Information [Line Items]
Net revenue by product Line									$ 69,622	$ 99,762	$ 88,534

Geographic and Segment Informat

Geographic and Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Schedule of Geographic and Segm

Schedule of Geographic and Segment Data (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenue	$ 83,107	$ 75,199	$ 77,345	$ 82,645	$ 83,561	$ 65,359	$ 69,194	$ 70,869	$ 318,296	$ 288,983	$ 244,750
Long-lived assets	158,140				181,440				158,140	181,440	74,417
Depreciation and amortization expense									13,681	9,524	7,074
Equity in net income of joint ventures									2,569	3,987	2,395
Operating income (loss)	(47,265)	$ 1,742	$ 1,191	$ (189)	5,050	$ 4,044	$ 3,318	$ 6,632	(44,521)	19,044	31,380
Interest expense									770	2,188	930
Interest income and other									(2,790)	375	205
Income tax provision (benefit)									(26,199)	(20,773)	895
Capital expenditures									(6,711)	(4,242)	(1,103)
Deferred tax assets	50,808				23,778				50,808	23,778	6
Investment in joint ventures	7,108				4,539				7,108	4,539	2,063
Total assets	349,732				379,958				349,732	379,958	310,208
Sagent US
Segment Reporting Information [Line Items]
Net revenue									287,612	280,422	244,750
Long-lived assets	80,947				91,417				80,947	91,417	74,417
Depreciation and amortization expense									8,826	8,188	7,074
Equity in net income of joint ventures									2,569	3,987	2,395
Operating income (loss)									(43,769)	21,700	31,380
Interest expense									564	1,979	930
Interest income and other									(2,495)	375	205
Income tax provision (benefit)									(25,993)	(20,034)	895
Capital expenditures									(1,447)	(3,510)	(1,103)
Deferred tax assets	50,808				23,778				50,808	23,778	6
Investment in joint ventures	7,108				4,539				7,108	4,539	2,063
Total assets	258,275				272,283				258,275	272,283	310,208
Sagent US | United States
Segment Reporting Information [Line Items]
Net revenue									286,773	280,339	244,272
Long-lived assets	80,947				37,252				80,947	37,252	17,401
Sagent US | Other
Segment Reporting Information [Line Items]
Net revenue									839	83	478
Sagent US | China
Segment Reporting Information [Line Items]
Long-lived assets					52,635					52,635	$ 57,016
Omega
Segment Reporting Information [Line Items]
Depreciation and amortization expense									4,855	1,336
Operating income (loss)									(752)	(2,656)
Interest expense									206	209
Interest income and other									(295)
Income tax provision (benefit)									(206)	(739)
Capital expenditures									(5,264)	(732)
Total assets	91,457				107,675				91,457	107,675
Omega | Canada
Segment Reporting Information [Line Items]
Net revenue									30,684	8,561
Long-lived assets	$ 77,193				$ 91,553				$ 77,193	$ 91,553

Management Transition - Additio

Management Transition - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Payment of management transition cost	$ 4,019
Management transition	5,310
Accounts Payable and Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Management transition costs	$ 1,291

Components of Loss Before Incom

Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic	$ 8,931	$ 30,200	$ 36,671
Foreign	(57,012)	(14,022)	(6,182)
Income (loss) before income taxes	(48,081)	16,178	30,489
United States federal:
Current	20	943	895
Deferred	(25,887)	(21,089)
Federal income tax expense (benefit)	(25,867)	(20,146)	895
State and local:
Current	937	1,853
Deferred	(1,063)	(1,740)
State and local income tax expense (benefit)	(126)	(113)
Total United States	(25,993)	(22,964)	895
Outside United States:
Current	898	205
Deferred	(1,104)	(944)
Total outside United States	(206)	(739)
Provision (benefit) for income taxes	$ (26,199)	$ (20,773)	$ 895

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Benefit/provision from income taxes		$ 25,308
One-time permanent benefit from discontinued operation worthless stock and bad debt deductions	$ 30,041
Net Operating Loss Carryforwards	81,035
Deferred tax assets, net	$ 50,808	23,778	$ 6
Tax year under examination	2,013
Unrealized tax benefits arising from tax deductions for share based compensation in excess of the compensation recognized for financial reporting purposes	$ 3,100
Unrecognized tax benefits	726	659
Unrecognized tax benefits that would impact effective tax rate	588
Unrecognized tax benefits expected to be resolved in the next 12 months	120
Accrued interest and penalties	24	20
Interest and penalties expense	4	20
Unrecorded Adjustment
Income Tax Disclosure [Line Items]
Benefit/provision from income taxes		$ 23,778
SCP
Income Tax Disclosure [Line Items]
One-time permanent benefit from discontinued operation worthless stock and bad debt deductions	30,041
Deferred tax assets, net	$ 14,126
State and Foreign Country Jurisdiction | Minimum
Income Tax Disclosure [Line Items]
Income tax returns, statute of limitations period	3 years
State and Foreign Country Jurisdiction | Maximum
Income Tax Disclosure [Line Items]
Income tax returns, statute of limitations period	5 years
Earliest Tax Year
Income Tax Disclosure [Line Items]
Tax year remain subject to examination	2,012
Expiring Between 2016 and 2020
Income Tax Disclosure [Line Items]
Net Operating Loss Carryforwards	$ 48,904

Net Operating Loss Carry Forwar

Net Operating Loss Carry Forwards (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	$ 81,035
2,032
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	300
2,034
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	410
2,036
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	$ 80,325

Reconciliation of Income Tax Pr

Reconciliation of Income Tax Provision (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Provision (benefit) at statutory rate	$ (16,828)	$ 5,662	$ 10,366
State income taxes, net of federal income tax	(373)	1,750	230
Foreign rate differential	5,731	1,392	560
Valuation allowance	14,126	(28,672)	(9,998)
Worthless stock and bad debt deductions	(30,041)
Uncertain tax positions	101	541
Permanent book / tax differences	164	172	(263)
Change in tax rate	89	(1,498)
Other	832	(120)
Provision (benefit) for income taxes	$ (26,199)	$ (20,773)	$ 895

Deferred Income Tax Assets and

Deferred Income Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Product development and start-up costs	$ 14,005	$ 12,702
Inventory	3,539	2,493
Loss and credit carryforwards	40,358	9,664
Bad debt reserves	16	549
Accrued expenses / other	4,373	5,244
Deferred compensation	2,979	3,155
Depreciation and amortization	11,482
Alternative minimum tax carryforwards	1,555	1,546
Total deferred tax assets	78,307	35,353
Deferred tax liabilities:
Depreciation and amortization	(3,850)	(2,799)
Intangible assets	(11,070)	(14,351)
Inventory	(99)	(180)
Total deferred tax liabilities	(15,019)	(17,330)
Net deferred tax asset	63,288	18,023
Valuation allowance	(24,501)	(9,950)
Net deferred tax assets (liabilities)	$ 38,787	$ 8,073

Summary of Unrecognized Tax Ben

Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Beginning of year	$ 659
Increases from prior year tax positions	136	$ 719
Decreases relating to settlements with taxing authorities	(85)	(60)
Increases from current year positions	16
End of year	$ 726	$ 659

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Oct. 13, 2015USD ($)	Dec. 31, 2015USD ($)Product	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Commitments and Contingencies [Line Items]
Agreement, optional renewal period		2 years
Notice period required prior to expiration of renewal term		2 years
Total rental expense		$ 664	$ 656	$ 431
Payments for patent infringement	$ 5,000
Settlement amount received	$ 1,477
Legal settlement expense reimbursement amount		607
Legal settlement expense		$ 2,447
Dobfar Spa
Commitments and Contingencies [Line Items]
Agreement, initial expiration date		Jul. 7, 2016
Gland Pharma Limited
Commitments and Contingencies [Line Items]
Agreement, optional renewal period		1 year
Notice period required prior to expiration of renewal term		24 months
Agreement, initial expiration date		2016-06
Number of Products | Product		5
Product currently marketed | Dobfar Spa
Commitments and Contingencies [Line Items]
Number of products covered by the agreement | Product		7
Product currently marketed | Dobfar Switzerland
Commitments and Contingencies [Line Items]
Number of products covered by the agreement | Product		3
Zoledronic acid products
Commitments and Contingencies [Line Items]
Payment to acquire future license to sell products		$ 1,683

Contingent Contractual Payments

Contingent Contractual Payments (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 18,037
2,017	4,124
2,018	3,726
2,019	709
2,020	60
2021 and Thereafter	1,065
Total	$ 27,721

Future Annual Minimum Lease Pay

Future Annual Minimum Lease Payments Related to Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 805
2,017	501
2,018	516
2,019	532
2,020	404
2021 and Thereafter	134
Total	$ 2,892

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Due from related party	$ 2,678	$ 2,156
Due to related party	13,754	8,079
Dividends paid		1,511	$ 4,318
Sagent Agila LLC
Related Party Transaction [Line Items]
Due from related party	2,678	2,156
Due to related party	13,754	8,079
Dividends paid		1,511
Sagent Agila LLC | Distribution Joint Ventures
Related Party Transaction [Line Items]
Dividends paid	$ 0	$ 3,022

Quarterly Financial Data (Detai

Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 83,107	$ 75,199	$ 77,345	$ 82,645	$ 83,561	$ 65,359	$ 69,194	$ 70,869	$ 318,296	$ 288,983	$ 244,750
Gross profit	23,011	24,362	18,441	21,925	24,416	18,770	22,592	20,384	87,739	86,162	77,522
Income (loss) from continuing operations	(47,265)	1,742	1,191	(189)	5,050	4,044	3,318	6,632	(44,521)	19,044	31,380
Net income	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Weighted-average shares used to compute net income per share
Basic	32,793	32,747	32,161	32,043	31,945	31,895	31,873	31,814	32,439	31,882	29,213
Diluted	32,793	32,747	32,161	32,043	33,031	32,960	32,665	32,614	32,439	32,745	29,937
Net income per share
Basic	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.84	$ 0.06	$ 0.10	$ 0.16	$ (0.67)	$ 1.16	$ 1.01
Diluted	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.81	$ 0.06	$ 0.09	$ 0.16	$ (0.67)	$ 1.13	$ 0.99

Quarterly Financial Data - Addi

Quarterly Financial Data - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information [Line Items]
Net income (loss)	$ 17,937	$ 1,795	$ 256	$ 1,894	$ 26,837	$ 1,926	$ 3,069	$ 5,119	$ (21,882)	$ 36,951	$ 29,594
Net income (loss) per diluted share	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.81	$ 0.06	$ 0.09	$ 0.16	$ (0.67)	$ 1.13	$ 0.99
Net income (loss) per basic share	$ (0.55)	$ (0.05)	$ (0.01)	$ (0.06)	$ 0.84	$ 0.06	$ 0.10	$ 0.16	$ (0.67)	$ 1.16	$ 1.01
Unrecorded Adjustment
Quarterly Financial Information [Line Items]
Net income (loss)										$ (2,930)
Net income (loss) per diluted share										$ (0.09)
Net income (loss) per basic share										$ (0.09)

Valuation and Qualifying Acc122

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Chargeback Allowance
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	$ 63,088	$ 43,682	$ 24,265
Valuation Allowances and Reserves, Charged to Cost and Expense	318,605	403,493	300,835
Valuation Allowances and Reserves, Deductions	333,105	384,087	281,418
Valuation Allowances and Reserves, Ending Balance	48,588	63,088	43,682
Allowance for Cash Discounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	2,440	2,414	1,373
Valuation Allowances and Reserves, Charged to Cost and Expense	15,655	13,364	12,204
Valuation Allowances and Reserves, Deductions	14,178	13,338	11,163
Valuation Allowances and Reserves, Ending Balance	3,917	2,440	2,414
Allowance for Credits
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	15,860	4,895	3,262
Valuation Allowances and Reserves, Charged to Cost and Expense	6,626	23,406	6,760
Valuation Allowances and Reserves, Deductions	15,444	12,441	5,127
Valuation Allowances and Reserves, Ending Balance	7,042	15,860	4,895
Deferred Tax Valuation Allowance
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	9,950	42,109	46,657
Valuation Allowances and Reserves, Charged to Cost and Expense	15,094	11,164	1,158
Valuation Allowances and Reserves, Charged to Other Accounts			5,843
Valuation Allowances and Reserves, Deductions	544	43,323	11,549
Valuation Allowances and Reserves, Ending Balance	24,500	9,950	42,109
Inventory Reserve Allowance
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	3,242	5,099	2,021
Valuation Allowances and Reserves, Charged to Cost and Expense	2,097	2,238	3,078
Valuation Allowances and Reserves, Charged to Other Accounts		508
Valuation Allowances and Reserves, Deductions	339	4,603
Valuation Allowances and Reserves, Ending Balance	5,000	3,242	5,099
Allowance for doubtful accounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	1,433	23	124
Valuation Allowances and Reserves, Charged to Cost and Expense	312	1,440
Valuation Allowances and Reserves, Deductions	1,702	30	101
Valuation Allowances and Reserves, Ending Balance	$ 43	$ 1,433	$ 23